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Abstract
It is believed that the formation of DNA adducts is an essential initial step in carcinogenesis.
To better understand this initial step and its relationship to cancer, this study primarily focuses on
benzo(a)pyrene (BaP), a highly carcinogenic model polycyclic aromatic hydrocarbon (PAH) and an
ubiquitous environmental contaminant. The objective of this dissertation was to identify and
quantify carcinogen-DNA adducts as biomarkers of exposure to BaP.
The BaP-DNA adduct levels were measured by Adduct Detection by Acylation with
Methionine (ADAM), a new postlabelling method that was recently developed by our group.
Nucleoside adducts of fluoranthene, 4-aminobiphenyl and 8-hydroxy-2'-deoxyguanosine (8-OHdG)
were acylated with 3SS-methionine and detected in femtomolar quantities. This method was
adapted for analysis of BaP-DNA adducts and optimized with 3H-BaP using unlabeled methionine.
Acylated products of benzo(a)pyrene-deoxyguanosine (BaP-dGuo) from different sources,
including 3H-BaP-dGuo isolated from calf thymus DNA modified enzymatically in vitro or by
reaction with BPDE, have shown identical RP-HPLC retention times. The 35S content of acylated
products was linearly correlated (r = 0.860) with the nucleoside adduct concentration over the
range from 20-1000 femtomoles.
BaP-DNA adduct levels in random human lung samples were found to range from 240-51,120
adducts per cell. Similarly, paraffin-embedded breast tissues contained BaP-DNA adduct levels
from 35-1764 adducts in 10' normal nucleotides (0.05-14.7 femtomole BaP/pg DNA) with an
average of 44,000 adducts/cell.
Adult CD-1 mice were injected i.p. with [3H]-benzo(a)pyrene ([3H]-BaP) (2mg, 117
mCi/mmol) and sacrificed 24 hr later. Liver DNA was isolated, enzymatically hydrolyzed to
nucleosides, purified by immunoaffinity chromatography and analyzed with the ADAM procedure
for BaP-DNA adducts. BaP-DNA adduct levels were quantified by both radioactivity (3H in BaP)
and acylation with 35S-methionine with the ADAM procedure. An excellent correlation was found
between the adduct levels determined independently by 3H and '3S. A newborn mouse lung
adenoma assay was used to generate information about BaP-DNA adducts formed in vivo.
Newborn CD-1 mice were injected i.p. with a tumorigenic dose of 210 p.g of BaP (0.83mmole)
three times over a two week dosing regimen starting at birth. Control mice were given DMSO as
placebo. The mice were sacrificed by decapitation at specific time points of 24 hr, 72 hr, 1 wk and
5.5 months. Both target (lung) and nontarget (liver, kidney) tissues were collected. Tumors were
induced by this regimen in the male mice. DNA was isolated, enzymatically hydrolyzed to
nucleosides, purified and analyzed with the ADAM procedure for BaP-DNA adducts. The RP-
HPLC profiles of treated mice were compared with their prospective controls. Relationships of
adduct levels to tumorigenesis were summarized.
Successful acylation conditions were used to analyze benzo(a)pyrene adducts in DNA
extracted from samples of tissues of CD-1 mice injected with benzo(a)pyrene and samples of
human lung and embedded breast tissues. RP-HPLC profiles of the acylation products of adducts
isolated from mouse tissues and human lung samples eluted at the same retention time as that of an
authentic BaP-dGuo standard.
The postlabelling method combined with a subsequent RP-HPLC profile allows
characterization of the carcinogen-DNA adducts present in the tissues. A data base will be
generated to analyze DNA as a dosimeter of exposure. This data base will be used to correlate
molecular biomarkers, specifically BaP-DNA adducts with tumor frequency. A direct relationship
will verify the use for carcinogen-DNA adducts as dosimeters of exposure to genotoxic chemicals
and will be imperative in understanding the role carcinogens play in initiating cancer.
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Chapter 1. Introduction
Polycyclic aromatic hydrocarbons (PAHs) are released into the environment by the
burning of organic materials such as coal, fuel oils, petrol, wood, refuse, and various plant
materials. The main sources of exposure for human populations include coke plants, which
account for 30% of airborne PAHs, coal-fired power plants and domestic coal- and wood-
burning stoves. Other contributions to air pollution are industrial activity, automobile traffic
and the burning of coal for domestic use. Higher concentrations of atmospheric PAHs are
found in urban areas in western countries (up to 10 ng/m3 of benzo(a)pyrene (BaP)). These
carcinogens are metabolized to reactive intermediates which covalently bind to cellular
molecules, resulting in DNA adducts and protein adducts. Traditionally, measurements of
contaminants in the environment (e.g. air, soil, water, food) have been used for assessment
of exposure. These measurements make it difficult to assess human exposure to polycyclic
aromatic hydrocarbons, since exposure to PAHs occurs mainly through inhalation, ingestion
and skin absorption (Oesch, 1983). Accurate measurements of individual exposure, such as
DNA damage as a result of exposure to environmental carcinogens may be used to
appropriately assess human health risk factors for cancer.
It is believed that the formation of DNA adducts is an essential initial step in
carcinogenesis. Concentrating investigation efforts towards DNA-adducts in the target cells
will help to decipher the relationship between dose and exposure in human populations. The
objective is to identify and quantify carcinogen-DNA adducts as biomarkers of exposure to
genotoxic chemicals. The need for validated sensitive methods to determine carcinogen
exposure in an individual is imperative. The BaP-DNA adduct is a form of genetic damage
and may lead to mutations. The appearance of a stable adduct may give way to the loss of a
base or the insertion of an incorrect base during DNA repair. A mistake in the coding could
lead to errors in transcription to mRNA or in translation to protein. The resulting faulty
protein may could be a regulatory protein that is normally responsible for growth or the
halting of growth. The error may result in over-expression or under-expression of a
regulatory growth protein, thereby resulting in tumor formation.
To better understand how DNA adducts are related to cancer, this research focuses on
benzo(a)pyrene (BaP) since it is a highly carcinogenic PAH and a ubiquitous environmental
contaminant (Zaleski, 1991). Chapter 2 reviews the literature discussing the carcinogenicity
of BaP demonstrated in animals and the advantages and disadvantages of techniques that
measure BaP in humans. The major objective of this body of work was to further develop the
ADAM method created in the Wogan laboratory and apply it to the identification and
quantification of carcinogen-DNA adducts. The ability to measure BaP-DNA adducts will
make it possible to examine the relationship between BaP-DNA adducts and exposure to BaP.
The synthesis of an internal benzo(a)pyrene-nucleoside adduct is described in Chapter 3.
Chapter 4 outlines the optimal digestion and purification conditions obtained through the use
of in vitro-modified DNA. Chapter 5 describes the application of the method to quantify
DNA adduct levels in animals treated with BaP. The method was applied to mouse tissues to
determine the level of BaP-DNA adducts formed in vivo. This includes the newborn mouse
lung adenoma assay in which newborn CD-i mice were injected i.p. with a tumorigenic dose
of 210 pg BaP/35 pl DMSO three times over a two week period. Both target (lungs, livers)
and nontarget (kidneys) tissues were collected and analyzed via the ADAM procedure for
BaP-DNA adducts. The postlabelling method combined with a subsequent HPLC profile
allowed the characterization of the carcinogen-DNA adducts present in the tissues.
The final goal is to analyze BaP-DNA adducts in human tissues. Chapter 6 describes the
successful application of the ADAM method to analyze BaP-DNA adducts in human lungs
and embedded breast tissues. The conclusions are summarized in Chapter 7 which also
outlines ideas for future work. A data base will be generated to analyze DNA as a dosimeter
of exposure. This data base will be used to correlate molecular biomarkers, specifically
BaP-DNA adducts with tumor frequency. A direct relationship will verify the use for
carcinogen-DNA adducts as dosimeters of exposure and will be imperative in understanding
the role carcinogens play in initiating cancer.
Chapter 2 Literature Survey
2.1 Polycyclic aromatic hydrocarbons
2.1.1 Source and composition
Polycyclic aromatic hydrocarbons (PAHs) are released into the environment by the
burning of organic materials such as coal, fuel oils, petrol, wood, refuse, and various plant
materials. The main sources of exposure for human populations include coke plants, accounting
for 30% of airborne PAHs (Harris, 1989), coal-fired power plants and domestic coal-burning and
wood-burning stoves. Other contributions to air pollution are industrial activity, automobile
traffic and the burning of coal for domestic use. Higher concentrations of atmospheric PAHs are
found in urban areas in western countries (up to 10ng/m' of benzo(a)pyrene) (Hemminki, 1990).
BaP is a highly carcinogenic PAH and an ubiquitous environmental contaminant. Human
exposure to BaP can be as high as 100 ng/m3 in heavily polluted air, 23 ng/m3 in drinking water,
and 100 gtg/kg in smoked foods. Exposures are particularly high for coke oven workers, gas
works operators and asphalters, whose occupations have been associated with increased cancer
risk. It is important to better understand the relationship between an increase exposure to BaP
and an increase in cancer risk.
2.1.2 Metabolism and biological effects of BaP
PAHs are metabolized to reactive intermediates which covalently bind to cellular
molecules, resulting in DNA adducts and protein adducts. The metabolism of BaP takes place in
two phases. Phase I involves the conversion, by oxidative enzymes and epoxide hydrolases
attached to the microsomal membrane, to oxidized derivatives (epoxides, phenols, quinones) is
performed. The oxygenase is also know as "aryl hydrocarbon hydroxylase' (AHH). In phase 2,
these polar metabolites are conjugated with glutathionine by enzymes mainly present in the
cytosol which make the substances soluble enough to be excreted (Osborne and Crosby, 1987).
Figure 2.1 illustrates the microsomal activation of BaP which covalently binds
deoxyguanosine. The biologically active important metabolites of benzo(a)pyrene are the diol
epoxides 7,8-dihydroxy-9,10-epoxybenzo(a)pyrene (BPDE) in which the epoxide group is
situated in the bay region of the molecule (C'0 -C1 ). The most abundant reaction products of the
(+) and (-) anti-BPDE enatiomers with native DNA are adducts with a covalent linkage between
the C'O position of BPDE and the exocyclic amino group of deoxyguanosine residues (Geacintov
et al., 1997). There are two diasterereomeirc forms of each diol epoxide that are distinguished
from one another because the most distant hydroxyl group can either be anti or syn relative to the
orientation of the epoxide group. In the case of the bay region BaP diol epoxides, each of the two
diasteromers, 7r, 8t-dihydroxy-t9,10-epoxy and 7r,8t-dihydroxy-c9, 10-epoxy-7,8,9, 10-
tetrahydrobenzo(a)pyrene (called anti- and syn-BPDE, respectively), can be resolved into two
optically active (+)- and (-)-enantiomers. For anti-BPDE, the absolute configurations of the two
enantiomers are (+)-7(R),8(S),9(S),10O(R) and (-)-7(S),8(R),9(R),10(S) ((+)- and (-)anti-BPDE
respectively). The 4 adduct conformations for the DNA lesion are stereoisomers but chemically
identical. They are (+)-trans-, (-) trans-, (+)-cis-, and (-)-cis-anti-BP-N2-dG. The major adduct
formed by the metabolism of BaP arose from the trans addition of 7R-anti-BPDE to the amino
group of deoxyguanosine (Osborne and Crosby, 1987). The newly formed compound,
BaP-DNA adduct, is a form of genetic damage and may lead to mutations. It is believed that
DNA adducts are an essential initial step in carcinogenesis since these mutations could activate an
oncogene or inactivate a tumor suppressor gene resulting in uncontrollable growth.
In experiments where the binding of BaP to DNA was examined (Meehan et al., 1977),
two adducts were obtained for both deoxyguanosine and deoxyadenosine. The formation of the
two adducts could have resulted from the reaction with both stereoisomers of (±) BaP diol
epoxide or alternatively, a single isomer forming cis and trans addition products. High-resolution
mass spectroscopy has quantitatively determined that the exocyclic amine of guanine is the
preferred binding site. The excision repair of adenine carcinogen adducts in a number of cases is
known to occur at a greater rate than those of deoxyguanosine (Dipple, 1977). The N2-exocyclic
amine adduct of deoxyguanosine may therefore have a relatively long biological half life (Meehan,
1977).
The exocyclic amino groups of purine residues in native DNA are the primary targets of
the covalent binding reactions of PAH diol epoxides. The attachment of PAH diol epoxides to
the N2 groups of guanine or N' of adenine residues can occur by either trans or cis addition. Thus
each PAH diol epoxide entiomer can give rise to two adducts with different absolute
configurations about the PAH-exocyclic amino group linkage site. The spectrum of adducts
fromed when (+)- or (-)-anti-BPDE reacts with nucleic acids in an aqueous environment depends
on the nucleic acid composition, secondary structure of the DNA, solution composition, etc.
Cheng et al., (1989) reported typical results on the binding of these two entionmers to native
DNA. In the case of the (+)anti-BPDE enantiomer, the dominant adduct (>90%) is the (+)-trans-
anti-BPDE-N2-dG. Whereas in the case of of (-) anti-BPDE, a smaller proportion of (-)-trans-
adducts (63%) but greater proportions of (-)-cis-anti-BPDE-N2-dG (22%) and (-)-trans-anti-
BPDE-N6-dA adducts (15%) were found.
There are several things known about the properties of DNA containing BPDE adducts.
The bound BPDE can be detected by fluorescence and the spectrum is similar to that of BPDE
(Osborne and Crosby, 1987). The temperature at which the double stranded structure breaks up
("melting point") is lowered by treatment with BPDE. This implies that the modified bases do not
properly fit into the normal DNA structure. When anti-BPDE or syn-BPDE was incubated at
neutral pH, apurinic sites developed which gave rise to single strand breaks in alkaline conditions
(Shooter et al., 1977). These sites resulted mainly from the loss of BPDE-7-guanine adduct from
the DNA (Osborne and Merrifield, 1985).
There are two types of anti-BPDE adducts that have been characterized on the basis of
how the BaP molecule is aligned with the DNA. Type I adducts have the pyrene chromophore
intercalated into the DNA structure. This minimizes the contact of the hydrophobic flat aromatic
ring systmes with the aqueous solvent environment. This binding is noncovalent. Type II adducts
describe the external binding of the BaP molecule, lying outside of the DNA bases. These react to
form covalent adducts. Based on UV optical characteristics of anti-BPDE-polynucloetide and
stereochemically defined, site specific oligonucleotide adducts, it was shown that trans-anti-
BPDE-N2-dG adducts have type II conformations, while the isomeric cis-adducts have type I
conformations (Geacintov, 1991; Geacintov, 1997).
The biological activities of racemic anti-BPDE have been investigated more extensively
that those of the syn diastereomer. Racemic anti-BPDE is known to cause mutations in the
critical codons 12 and 61 of the human c-Ha-rasl protoncogene (Vousden et al.,1986). Since the
(+)-anti-BPDE is highly tumorigenic while the (-)-anti-BPDE is not (Buening et al., 1978, Slaga
et al., 1979) and the (+)-anti-BPDE is more mutagenic in mammalian cell systems (Brookes
1982), it seems that the chirality exerts a influence on the biological activities ofanti-BPDE
(Geacintov et al., 1997).
Bulky PAH-DNA lesions are known to stall DNA polymerases at or near the sites of the
adducts which could allow for the formation of bulged intermediates in which the modified nucleic
acid residues are no longer paired with their partner bases on the complementary strands
(Geacintov, et al, 1997). Such slipped, misaligned framshift intermediates are believed to give rise
to deletion and point mutations (Shibutani et al., 1993).
2.1.3 Selection of benzo(a)pyrene
Benzo(a)pyrene was isolated from coal tar in 1930. Upon application of BaP synthesized
by Cook et al. (1933) to the backs of 10 mice, tumors developed in all five of the surviving
animals. Since then, many researchers have tried to understand the mechanism by which BaP
causes cancer. To better understand how DNA adducts are related to cancer, this study proposes
to focus on benzo(a)pyrene. Benzo(a)pyrene was chosen in this study because it is a highly
carcinogenic PAH and it is ubiquitous in the environment and therefore may be relevant to human
cancer.
2.2 Dosimetry of exposure to genotoxic compounds
2.2.1 Covalent adducts as dosimeters
DNA adducts
The level of binding of BaP to DNA applied to mouse skin has been determined many
times (Phillips et al., 1978; Pereira et al., 1979; Ashurst et al., 1983). When the mice of three
different strains were treated with 1 pmole BaP each, DNA isolated from the skin 19 hours later
contained about 29 nmole BaP, whether the strain was resistent or not. Tthis level was
approximately linear with dose. The extent to which BaP binds internally is less well known.
Dunn et al (1983) demonstrated that the extent of binding to DNA was proportional to the dose
over a wide dose range (10-7 to 10'3 g/mouse). A linear relationship was similarly found at low
dose for binding to liver, lung or stomach DNA (Adriaenssens et al., 1983)
Approaches for using DNA lesions, to elucidate dose-response relationships in
carcinogen-exposed humans, have been developed through molecular dosimetry. Molecular
dosimetry can measure an individual's exposure after taking into account differences in
absorption, distribution, biotransformation and DNA repair. This is more accurate for dose-
response relationships than determining external exposure. The challenge in measuring DNA
lesions in humans is that they occur in relatively low quantities. The upper limit in humans is
about 100 fmole/mg DNA (3 DNA lesions per 105 normal nucleotides) (Lohman, 1992). The
disadvantage is that samples of human target tissues cannot be collected routinely. However,
surrogates like DNA from nucleated blood cells must be used if the level of DNA adducts in
target and surrogate tissues is parallel.
Protein adducts
Adducts to serum albumin and to hemoglobin (Hb) are the protein adducts used for
molecular dosimetry in humans. Protein adducts in hemoglobin and serum albumin can be
analyzed by physicochemical methods. These include gas chromatography (GC)-MS or by
immunoassay (Wogan, 1992). Hb adducts have been used to monitor occupational exposures.
HPLC combined with synchronous scanning fluorescence spectroscopy allowed for the detectin
of covalently bound BaP residues in Hb and DNA (Weston et al., 1989).
Protein adducts have several advantages. They are generally easier to collect than DNA
adducts and therefore can be obtained in large quantities. Since they have a relatively low
turnover rate they are useful in determining accumulated exposure.
DNA adduct and protein adduct analyes have been useful in the detection and
quantification of exposure through occupation, smoking and dietary contamination. The
measurement of DNA and protein adducts is designed to serve as a marker of exposure and
biologically effective dose. The pattern of DNA adducts formed can be altered by repair
mechanisms and by different tissues and cell types. The replication of carcinogen-modified DNA
can result in the fixation of a mutation which could be the initial carcinogenic step (Wogan, 1992).
2.2.2 Relevance of covalent modification of DNA to carcinogenesis
Evidence suggests that there is a relationship between adduct levels and the promotion of
tumors. A linear dose-response relationship up to the dose of 1mg/kg was found when BaP was
administered to rats by single injection over the dose range of 4 gg/kg to 4 mg/kg body weight
(Lutz, 1978). Animals were sacrificed 50 hours later and total carcinogen binding to liver DNA
determined. The dose response relationship was nonlinear at higher doses. This direct
relationship between binding level and dose over a wide dose range (10-' to 10-3g/mouse) was
found when BaP-DNA adduct levels were measured in target (stomach) and nontarget (liver)
organs of mice (Dunn, 1983; Wogan and Gorelick, 1985) A significant consideration in
determining the carcinogenicity of BaP is the extent to which the DNA adducts are repaired
and/or persist in the target organ. For example, DNA adducts were measured in skin epidermis
(Albert, et al ) by ELISA method in mice given single weekly application of BaP (8 gg-64 pg).
The linear increase in DNA adducts was not as steep above the 32 gtg/week, yet there was a sharp
rise in tumor response above the 32 gg/week dose rate. All of the tumors were initially
papillomas, which converted to carcinomas after an average of 8 weeks.
32 P-Postlabelling analysis revealed the presence of multiple adducts in the WBC DNA of
smokers with a total concentration of 1 adduct in 108-10o' normal nucleotides (Jahnke et al.,
1990).
2.2.3 Methods for detecting carcinogen-DNA adducts
To study the interaction of BaP with DNA, sensitive methods are necessary to detect
DNA-bound BaP in experimental models or in exposed individuals.
Immunoassays
Using antibodies to detect BaP-DNA adducts has the advantage of having high specificity
for BaP or for one particular BaP-nucleoside adduct. In the immunological approach of detecting
carcinogens, monoclonal or polyclonal antibodies are raised against either carcinogen-modified
DNA or carcinogen-nucleoside DNA adduct coupled to protein carriers. The antibodies are then
used to quantify specific adducts in the DNA of exposed cells. The antiserum of the animal can
be used in several ways (Osborne and Crosby, 1987): (1) Radioimmunoassay: Antiserum was
raised in rabbits by injecting an (+)-anti-BPDE-DNA+methylated bovine serum albumin comples.
Samples were tested by determining how much they competitively inhibited the reaction between
this antiserum and tritiated (+)-anti-BPDE-DNA (Poirier et al., 1980). (2) Enzyme-linked
immunosorbent assay (ELISA): The immunoprecipitate was detected by linking it to an enzyme,
e.g. with a complex consisting of goat antibody to rabbit immunoglobin G and alkaline
phosphatase, and measureing the enzyme activity. This assay was reported to detect 0.1-0.4
fmole BaP adducts in 1tg of DNA (Hsu et al., 1981, Perera et al., 1982). (3) Visualization of
bound antibody. The antibody bound to BaP-DNA can be observed under a microscope after
labelling it with a fluorescein derivative, or individual molecules observed with an electron
microscope after labelling with a ferritin complex (Slor et al., 1981). (4) Monoclonal antibodies:
Cell lines created by fusing myeloma cells with spleen cells from mice treated with a BaP-protein
conjugate can be cloned to produce highly specific antibodies which will detect as little as 3 fmole
BPDE (Santella et al., 1984).
Fluorescence
In 1975, fluorescent spectra like that of BaP were obtained (Kodama and Nagata, et al.,
1975; Jerntrom et al.,1978). Up until then solutions of DNA from mouse skin or hamster embryo
cells treated with BaP were weakly flourescent (Daudel et al., 1975; Ivanovic et al., 1976). The
better fluorescence spectra have been obtained a number of ways: (1) Hydrolysis of the DNA:
The free bases, released from the polymer with mild acid gave better results because the
nucleosides have a higher fluorescence intensity and a clearer spectrum than the intact nucleic acid
(Osborne and Crosby 1987). Good results were obtained by treating DNA containing BPDE
adducts with acid at 80°C to release BaP-tetrahydro-tetrols which were seperated by HPLC and
quantified by their fluorescence (Rahn, et al., 1982; Shugart, et al., 1983). (2) Synchronous
fluorescence: By simultaneously scanning the excitation and emission wavelengths with a
difference of 34 nm, BaP-tetrahydrotetrols liberated from BaP-DNA with acid gave a sharp peak
at 379nm. This allowed the detection of adducts down to 1 in 107 DNA nucleotides (Vahakangas
et al., 1985). (3) Cooling to 77K. The fluoresence intensity is increased by a factor of 40
(Ivanovic et al., 1982). (4) Cooling to 4K and exciting with laser light at 377 nm. The emission
spectrum consisted of many sharp peaks (Heisig et al., 1984; Osborne and Crosby, 1987). The
fluorescence assays are sensitive but can only be used to quantitiate adducts that have fluorescent
characteristics.
Postlabelling
Aromatic carcinogen-DNA adducts have been analyzed via 2P-postlabelling techniques
(Randerath, 1989). This method involves enzymatic digestion of DNA to deoxynucleoside
3'monophosphates. A T4 polynucleotide kinase-catalyzed transfer of 2P from adenosine
(gamma-a2P)triphosphate converts the 3'monophosphates to deoxynucleoside
3',5'-(5'-32P)diphosphates. In previous adaptations of the approach, the DNAs were first digested
with a mixture of micrococcal nuclease (MN) and spleen phosphodiesterase (SPE), yielding
3'-monophosphates of normal (Np) and adducted nucleosides (Xp). The nucleotides were
subsequently converted to 5'-32P-labelled nucleoside 3',5'-bisphosphates by incubation with
(gamma-32P)-ATP and T4 polynucleotide kinase (PNK) (Randerath, 1981). The labelled adducts
are then purified and analyzed by thin-layer chromatography, autoradiography and scintillation
counting. This procedure detected 1 adduct in 10'-10lo nucleotides. This method was modified
for fluoranthene-DNA adducts with the use HPLC-liquid scintillation counting (Gorelick, 1989).
With both 32P-postlabelling techniques, the sensitivity was increased with the use of higher
amounts of DNA.
An alternative 32P-postlabelling procedure (Randerath, 1989b) introduced the use of
nuclease P 1 prostastic acid phosphatase (PAP) to generate a mixture of adducted dinucleoside
monophosphates (XpN) and normal nucleosides (N). The enzymatically enriched dinucleotides,
not the nucleosides are labelled at the 5'termini to yield 32P-labelled dinucleoside diphosphates
([32P]pXpN). The dinucleotides were either directly mapped by polyethyleneimine (PEI)-cellulose
TLC or cleaved with snake venom phosphodiesterase to produce 5'-monophosphates. Distinct
carcinogen-specific chromatographic profiles were generated by the adduct of the pX type and
differed from those of the corresponding dinucleotide (pbpN) and nucleoside bisphosphate (pXp)
adducts.
32P-postlabelling is very sensitive. It is reported to be able to measure 1 bulky adduct in
1010 normal nucleotides. The disadvantage is the cumbersome nature of the sheilding necessary
with the use of 32P. With regards to the applications that use TLC, the adduct spots are
sometimes not readily identifiedIn addition, there dependence on an enzymatic reaction for the
postlabelling of the adduct. The use of enzymes introduces complicated substrate kinetic factors
that can be difficult to account for. The use of 35S removes the need to use protective sheilding,
although proper procedures for the use of radioactive substances must be adhered to. Two
(35S)phosphorothioate postlabelling procedures for the HPLC analysis of PAH-DNA adducts have
been developed using 35S (Lau, 1991). BaP-modified DNA was digested to nucleotide
3'-phosphates by micrococcal nuclease and spleen phosphodiesterase and the adducted
nucleosides were extracted with 1-butanol. The adducted nucleoside-3'-phosphates were
5'-thiophosphorylated by T4 polynucleotide kinase (T4PNK) and adenosine
5'-O-(3-(sS)thiotriphosphate) to yield (35S)BaP-nucleoside-5'-phosphorothioate-3'-phosphate
adducts. (35S)BaP-nucleoside-5'-phosphorothioate adducts were also prepared using a nuclease
Pl/prostatic acid phosphatase DNA degradation method. There were no significant differences in
the HPLC profiles of the (35S)phosphorothioate-postlabelled adducts obtained from these two
procedures. This method sensitively measures PAH-DNA adduct but not non-PAH adducts.
In the Wogan laboratory, another postlabeling method (Sheabar, 1994) was developed
which subjects nucleoside adducts to acylation with 35S-methionine. This published method has
detected femtomolar (10"42 molar) quantities of dGuo, 4-ABP-dGuo and fluoranthene adducts. A
chromatographically pure adduct is incubated in the presence of t-butoxycarbonyl-L-methionine,
N-hydroxysuccinimidyl ester (TBM-NHS), tetrahydrafuran (THF) and pyridine for 2 hours at
37°C. The reaction mixture was dried, solvent extracted and analyzed via reversed phase HPLC.
The chemical reaction resulted in products that are more nonpolar and therefore appear later in
the chromatogram than the expected retention time of the adduct. Chromatograms generated in
the presence of TBM-NHS distinctly differ from reaction mixtures in the absence of TBM-NHS.
"3S has a half life 88 days which is more than 6 times longer than the half life of 32p (14 days) The
new method takes advantage of the long half life and the high specific activity at which the
product is available. The research in this thesis describes the further development of the method,
its validation to measure BaP-dGuo adducts and some recent improvements in the method.
2.2.4 Use of DNA adducts as molecular biomarkers of exposure
Smoking
Although many carcinogens have been identified in cigarette smoke, there is still
controversy about which carcinogens are predominately responsible for the development of lung
cancer. Smoking is a major source of BaP exposure at 20-50 ng/cigarette (Poirier, 1980) and is
considered to contribute to human lung cancer risk. The aryl hydrocarbon hydroxylase (AHH)
activity is believed to reflect the cytochrome P450IAl-mediated reactions which are expected to
control the rate at which aromatic carcinogen-derived electrophiles react with DNA in target cells
of the lung. An HPLC/fluorescent assay allowed the measurement of low levels of BaP-DNA
adducts in human lung (Alexandrov, 1992) and showed the formation of anti- and syn-BaP-DNA
adducts in lung samples of smokers. A positive correlation between the lung microsomal AHH
activity and the formation ofBaP-DNA adduct was shown. This finding is supported by Geneste
et al (Geneste, 1991), whose laboratory compared the pulmonary DNA adducts and AHH
activity. Non-tumorous lung specimens were collected from smokers and ex-smokers who were
undergoing thoracic surgery for malignant lung diseases. The four ex-smokers tested had
significantly lower amounts of DNA adducts in comparison to smokers. The levels ranged from
1-13 adducts /10' unmodified nucleotides in smokers and were of the same order of magnitude as
those reported in human bronchial epithelia of smokers (Phillips, 1990). It was found that the
AHH activity was significantly higher in smokers who had smoked until 1 week before surgery.
In addition a positive linear correlation was observed between DNA adduct levels and AHH
activity. This relationship could explain why AHH activity or inducibility appears to be a marker
for lung cancer risk in smokers (Petruzzeli, 1988). These findings are supported by another case
(Izzotti, 1991) where the presence of BaP-DNA adducts were investigated via synchronous
fluorescence spectrophotometry in cells, mostly pulmonary alveolar macrophages, recovered by
bronchoalveolar lavage. Out of the 39 individuals no adduct was detected in samples from
nonsmokers or ex-smokers, whereas 84.6% of samples from current smokers exhibited typical
fluorescent peaks The samples from 4 subjects that quit smoking during the last 6 months were
positive. It appears that when assessing the internal dose of inhaled BaP near target cells of the
respiratory tract, the detection of BaP-DNA adducts in alveolar macrophage represents a sensitive
biomonitoring tool.
Occupational exposure
Emissions from coke-ovens pose a significant risk of cancer to exposed coke workers
when monitoring human exposure. In a biomonitoring study (Haugen, 1986), in which the
BaP-DNA adducts were analyzed in coke oven workers, analysis of the topside coke-oven
samples from the work atmosphere showed that the exposure to PAH was high. Silesia is a highly
industrialized region in southern Poland and is at present one of the most polluted areas in the
world. Sensitive methods such as enzyme-linked immunoassays, synchronous fluorescence
spectrophotometry, and 32P-postlabelling assay, are used to detect carcinogen-DNA adducts in
exposed individuals. Enzyme-linked immunosorbent assay (ELISA) was used to analyze
peripheral while blood cells from Polish residents for the presence of PAH covalently bound to
DNA (Perera, 1992) in order to evaluate the biologic dose and effects of ambient pollution. The
32P-postlabelling method and sister chromatid exchange (SCE) measurement were performed on
the same blood samples to compare results. The two measures of adducts (ELISA and
32P-postlabelling) and SCE all demonstrated significant association with exposure as well as
seasonal variation. Adduct levels in industrialized residents were found to be 30.4 adducts/108
Jan-March and 4.2/10' in Sept-Oct whereas rural residents had levels at 11.01/108 and 3.0/108
respectively. This experiment was a follow up to a previous study which showed that residents of
industrialized towns in Poland had adduct levels and patterns similar to those of coke-oven
workers, but two to three times higher than those of residents in rural areas (Hemminki, 1990).
The large interindividual variation revealed by the biomarkers indicates individual differences in
exposure, metabolic activation of PAHs and/or repair of DNA. It is still unclear as to how the
variations in DNA repair rates influence in determining tissue site and risk of cancer in the general
population (Gorelick, 1989).
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Chapter 3. Synthesis of Benzo(a)pyrene-deoxyguanosine
3.1 Introduction
As discussed in Chapter 2, the metabolism of BaP has been extensively studied. Both in
vitro and in vivo studies have demonstrated that the major detectable BaP bound DNA adduct is
formed as a result of the BPDEI metabolite binding though the exocyclic amino group of
deoxyguanosine (Garner et al., 1985). In order to measure BaP-DNA adducts in human samples,
it is most important to have a method that has been validated. Since the goal is to measure BaP-
DNA adducts it is necessary to have a BaP-dGuo adduct standard to validate the method. A
standard had to be synthesized to determine the recovery ofBaP adducts and the efficiency of the
ADAM method.
There are numerous ways to generate a benzo(a)pyrene-deoxyguanosine adduct. The
early process incubated DNA (calf-thymus or salmon sperm) with benzo(a)pyrene and 3-
methylcholanthrene-induced rat liver microsomes. When radioactive BaP was used to generate
3H-BaP-dGuo, usually < 1% BaP was bound to the DNA. When commercially available BPDE
was reacted with calf-thymus DNA, polyG or oligonucleotides it resulted in 1-2% of the bases
being modified (Pulkrabek, 1977) or a modification level of 1.3% 3H-BaPDE-DNA (Tierney,
1977; Manchester, 1990).
This chapter describes the synthesis of the BaP-dGuo adduct. It was important that the
standard be in the nucleoside form so that the ADAM method could be used. In order to mimic
in vivo conditions the method using rat liver microsomes and 3H-BaP was chosen first. This was
important for producing the HPLC chromatograms. The modified DNA was digested to
nucleosides with a published hydrolysis procedure (Park et al, 1989) and an experimental one
used with the ADAM procedure. Once the recovery throughout the modification, digestion,
purification, and acylation process was determined, the goal was to scale up the production of the
standard. A large quantity was necessary to obtain structural information.
Since the efficiency of the microsomal reaction was low, the next step was to use the
procedure involving the commercially available anti-benzo(a)pyrene-diol-epoxide (anti-BPDE).
BPDE was reacted with 2'-dGuo and synthesized oligonucleotides. Several micrograms of BaP-
dGuo were produced to yield an electrospray-MS demonstrating the correct molecular weight.
The scale-up of this method produced the larger quantities (1 mg) of material needed but was not
pure enough for the NMR analysis of the acylation reaction products. Finally, it was possible to
obtain purified milligram quantities of the BaP-dGuo standard through an organic synthesis
procedure. The strategies and results of synthesizing the BaP-dGuo standard are reported here in
Chapter 3.
3.2 Methodology
3.2.1 Chemicals and Enzymes
Benzo(a)pyrene was obtained from Aldrich Chemical Company (Milwaukee, WI) and 3H-
BaP from Amersham. Anti-benzo(a)pyrene-r-7,t-8-dihydrodiol-t-9, 10-epoxide (+) is a product of
Midwest Research Institute (Kansas City, MO) and Chemsyn Science Laboratories (Lenexa, KS)
of NCI Chemical Carcinogen Reference Standard Repository (Frederick, MD). Rat liver cytosol
was prepared from postmitochondrial supernatant fraction (SL-9) supplied by Molecular
Toxicology (Annapolis, MD). All chemicals and solvents used were reagent grade. Calf thymus
DNA, glucose-6-phosphate, glucose 6-phosphate dehydrogenase and Nuclease P, (from
Penicillium citrinum) were purchased from Sigma Chemical Co. (St. Louis, MO). Snake venom
phosphodiesterase from Crotalus adamanteus was a product of ICN (Aurora, OH) and alkaline
phosphatase from bovine intestinal mucosa was purchased from Boehringer Mannheim
(Indianapolis, IN). Sep-pak C18 environmental cartridge was purchased from Waters (Milford,
MA);. Methanol was purchased from Baxter (McGaw, IL). Chloroform, benzene,
dichloromethane, ether, ethanol, were purchased from Mallinckrodt (Phillipsburg, NJ).
3.2.2 Preparation of modified DNA
Figure 3.1 summarizes the different ways to synthesize the BaP-dGuo adduct. Each
method is described below. Briefly, BaP modified DNA was made by incubating calf-thymus
DNA with BaP and rat liver microsomes or with BPDE. The modified DNA was isolated via
phenol:chloroform extraction and ethanol precipitation, followed by enzymatic hydrolysis to
nucleosides. The use of 2'-deoxyguanosine (2'-dGuo) was also used so that the DNA isolation
and enzymatic hydrolysis steps could be omitted.
Microsomal Activation of Benzo(a)pyrene
The method of synthesis of benzo(a)pyrene-deoxyguanosine was similar to the procedure
previously described (Gorelick & Wogan, 1989). To prepare in vitro modified DNA, calf thymus
DNA (2mg/ml) was shaken in HEPES pH 7.1 with 2.5-3.5 mg/ml microsomal protein, 0.8 mM
NADP +, 5 mM glucose-6-phosphate, 0.5 mM MgCl2, 0.4 units/ml glucose-6-phosphate
dehydrogenase, and 100 mM 3H-BaP (0.5-3 Ci/mmol) or 83 mM BaP in DMSO (1% total
volume). After 90 minutes, the reaction was terminated by the addition of SDS (to 1%) and NaCl
(to 250 mM). DNA was isolated by two extractions with an equal volume of phenol/chloroform
(1:1), followed by an extraction with chloroform alone until a clear interface was observed. DNA
was precipitated in cold ethanol and rinsed sequentially with benzene, chloroform,
dichloromethane, ethanol and ether before drying under nitrogen. The isolated DNA was
dissolved in water. Recoveries and binding levels were determined from absorbance at 254 nm
(20 OD units/mg DNA/ml) and the liquid scintillation counting of known amounts of DNA. The
BaP-DNA adduct was calculated by using the molar extinction coefficient of c=29,000 at 347nm
(Weinstein, et al., 1976).
Enzymatic Hydrolysis
Initially a published method (Park, et al.,1989) known to produce nucleosides from
PAH-modified DNA was used. This method of enzymatic hydrolysis used SVPD, AP, DNAse,
and spleen phosphodiesterase I (37°C, 2 hours). A single digestion procedure that could be used
to analyze more than one type of adduct would greatly enhance the flexibility of the ADAM
method. The method that was used in the Wogan laboratory for the optimization of the ADAM
method with 2-d-Guo and for the analysis of 4-ABP adducts is as follows: microsomally modified
calf thymus DNA (<1.7 mg/ml) was digested to nucleosides with nuclease P1 (76.5 units/mg),
0.450 ml 2 mM ZnCl2, 0.060 ml IM NaAc. The volume was brought up to 3 ml with distilled H20
and incubated for 1 hour at 370 C with agitation, covered with foil. An equal volume of IM Tris
buffer or IM carbonate buffer was added. Note: The carbonate buffer was later substituted for
the Tris buffer because the Tris was found to have contributed to the 35S background in the radio-
chromatogram. Snake venom phosphodiesterase (0.879 units/mg) and alkaline phosphatase (16.9
units/mg) were added and the reaction was incubated another hour at 370 C, with agitation. The
reaction mixture was stored at -200 C until ready for HPLC analysis. The RP-HPLC gradient used
was Gradient A. In order to establish that the digestion yielded nucleosides, a different HPLC
gradient (Gradient C as described in Table 3.1) was used and used acetonitrile and H20, pH 4.4.
Reaction of isomeric benzo(a)pyrene-diol-epoxide with DNA or 2'-Deoxyguanosine
Modification of several methods (Weinstein et al., 1976, Vahakangas et al., 1985,
Jeffrey et al., 1976) were used for the reaction of BPDE with calf thymus DNA, as follows:
2'-deoxyguanosine (20 mg) dissolved in 20 ml H20 was reacted with 5 mg
benzo(a)pyrene-diol-epoxide in 10 ml THF. The reaction mixture was incubated for 3-6 hours at
37°C in a shaking H20 bath, followed by extractions with 6 x 15ml H20-saturated ethyl acetate and
2 x 15ml H20-saturated diethyl ether. The aqueous phase was recovered. The amount of DNA
or deoxyguanosine was determined with absorbance at 254 nm. BaP was calculated by using the
molar extinction coefficient of 29,000 at 347 nm. The modified samples were scanned from
200-700 nm. Simultaneously, 3H-2dGuo (10 nmol, 31 Ci/mmol) was reacted with BPDE (0.81
mg) and taken through the same procedure. The rest of the 3H-dGuo-BaP was extracted and
evaporated. The pear shaped flask was washed 3 times with methanol and 3 times with H20.
The amount of 2-dGuo was determined from absorbance at 254 nm (20 OD units/mg
DNA/ml) or by scintillation counting for the 3H-dGuo (31 Ci/mmole). BaP was calculated by
using the molar extinction coefficient of e=29,000 at 347 nm. The modified samples were
scanned from 200-700 nm. The cold BPDE-dGuo was concentrated by evaporation unit and the
pear shaped flask was washed 3 times with methanol and 3 times with H20. The volume was
brought to 1.5 ml and stored until ready for HPLC analysis. At this time a microcolumn (1 gm)
was attached to the electrospray-MS. Gradient F was used at a flow rate of 0.1 ml/min.
Reaction of BPDE with oligonucleotides
Several researchers (Cosman, et al., 1990 ;Mao et al., 1995) found that the reaction of
BPDE with an oligonucleotide gave a 30% yield of BaP-dGuo. Oligonucleotides (IM and 10M
solutions) were purchased from MIT Biopolymers laboratory. A small scale reaction was
performed to determine whether the reaction would produce results similar to those in published
literature. The first oligonucleotide used was a 9mer d(ATATGTATA). A quantity of 1.5 pmol,
dissolved in 20 mM sodium phosphate, was incubated with 3.0 gmol BPDE (ratio 2 BPDE:1
oligonucleotide) dissolved in THF. All procedures were done under yellow lights. The mixture
was incubated overnight at room temperature, covered with foil and in the dark. The reaction
was analyzed by RP-HPLC with a Zorbax ODS column 4.6 x 250 mm, at room temperature with
a flow rate of 1 ml/min using Gradient D: A = 20 mM NaPhos pH 7.0, B = methanol, linear
gradient 0-90%B in 60 minutes. The peak at 20-25 minutes was collected and digested to
nucleosides as described previously, and analyzed by HPLC. A large scale reaction used 3
reaction vials (15 ml polypropylene tubes) each containing 10 pimol of oligonucleotide in 5 ml
NaPhos, pH 7.0 and 20 ýtmol of BPDE (6 mg) dissolved in THF and 1.5% TEA. Mao et al.
(1995) found that the addition of TEA increased the modification level. The HPLC anaylsis of
the reaction products used a C18 semi-preparative column at room temperature with a flow rate of
3 ml/min. Another oligonucleotide was found to yield a high percentage of BaP-dGuo (Liu,
1996). This 1 lmer d(CTAGGGTATC) 1.3 ptmole was reacted with BPDE (2.6 pimole).
Organic Synthesis of BaP-dGuo
A protocol was established (Seyedi, unpublished) for synthesis of the BaP-dGuo
adduct. The chemical strategy is shown in Figure 3.2. The BaP-dGuo was first protected with
benzyl groups, then incubated with BPDE overnight at 370 C, in the dark. The mixture was
deprotected and purified. The molecular weight was verified with electrospray-MS.
3.2.3 Chromatography
The samples were analyzed by reverse phase HPLC (model 126, Beckman
Instruments, Inc, Columbia, MD) equipped with diode array detector (model 168, Beckman
Instruments, Inc, Columbia, MD). A Zorbax-ODS 5 jtm column (4.6 mm x 250 mm, MacMod
Chadds Ford, PA) or an Microsorb 5 ipm C18 column (4.6 mm x 250 mm, Rainin, Woburn, MA)
was routinely used with the HPLC gradients are summarized in Table 3.1. The radioactivity was
determined on-line with a Radio-Chromatography Detector (Radiomatic Series A-280). Several
co-injections of the BaP-dGuo adduct generated with either microsomal activation or with BPDE
were analyzed via HPLC with the diode array detector fixed at 347 nm and 254 nm. The
oligonucleosides would have an absorbance at 254 nm and BPDE would have an absorbance at
347 nm. A radioactive chromatogram was also generated when possible. The 3H label on the
benzo(a)pyrene, when reacted with calf thymus DNA or on the deoxyguanosine, when reacted
with BPDE, would give a peak when present.
3.3 Results and Discussion
The reaction involving the modification of calf thymus DNA with 3H-BaP and microsomes
was repeated several times. Typically it resulted in a modification level of 1 BaP in 105 bases.
Table 3.2 summarizes several such reactions. The goal was to produce enough adduct to
generate HPLC chromatograms while validating the ADAM method. The specific activity had to
be high enough to be able to detect a signal. For example, a sample had to contain approximately
100,000 cpm to produce an acceptable chromatogram. The specific activity of the 3H-BaP ranged
from 125 mCi/mmole to 12,500 mCi/mmole. As the table shows, the higher the specific activity
of the 3H-BaP, the lower the modification level of the DNA. For example, the reaction using a
specific activity of 12,500 mCi/mmole resulted in a modification level of 1 BaP per 700,000 bases,
while a modification of 1 BaP in 11,000 was obtained with 3H-BaP at 500 mC/mmole. Therefore,
the specific activity of 3000 mCi/mmole was used for the rest of the microsomal modification
experiments. It consistently yielded a modification level of 1 BaP in 12,000-14,000 bases. The
recovery of the 3H-BaP-dGuo was monitored during the enzymatic hydrolysis and Sep-pak C 18
cartridge purification step. Fifty percent of the original adduct in the DNA was determined to be
recovered up to the step when it was ready for acylation.
Once the recovery of the processing was determined, the next step was to scale-up the
synthesis of the adduct. The goal was to make milligram quantities for the validation of the
ADAM method. This would allow structural characterization of the acylation products. A
comparison of modification procedures is shown on Table 3.3. The modification level was
increased by using the commercially available BPDE. BPDE reacted with 2'-deoxyguanosine
resulted in the highest modification level (1:793). The modified samples were scanned from 200
nm to 700 nm revealing a doublet peak from 200 nm to 300 nm (DNA or deoxyguanosine) and
between 320 nm to 350 nm (BaP). A typical scan is shown in Figure 3.3. The molecular weight
was confirmed by electrospray-MS. The molecular weight of the adduct is 569 yielding a peak at
m/z 570 in a protonated spectrum.
When the reaction of BPDE incubated with 2'-deoxyguanosine was scaled up to 100 mg of
DNA and 25 mg of BPDE, the amount of adduct recovered (0.1 mg) in the aqueous portion after
solvent extraction was considerably lower than expected (2 mg). The solvent extracts were found
to contain the adduct as revealed by HPLC analysis. The adduct was HPLC purified and the
molecular weight was determined by electrospray-MS. Even after HPLC purification, the adduct
was not pure. At this time a microcolumn (1 pm) was attached to the electrospray-MS. Gradient
F was used at a flow rate of 0.1 ml/min. There were 4 peaks detected with the same molecular
weight (m/z 570) and these peaks correspond to the 4 seen in the HPLC profile (Figure 3.12).
The timing on the gradient of the electrospray was different because of periodic machine failure;
however, the profile is the same. The two major peaks most likely correspond to the trans
isomers and the two minor peaks correspond to the two cis isomers. All four stereoisomers have
the same molecular weight.
3.3.1 HPLC analysis
In order to determine if the hydrolysis of the DNA yielded nucleosides, the hydrolysate
containing 50 pg of DNA was injected on the HPLC using gradient C. The peaks early in the
chromatogram correspond to dC, dG, dT and dA (Figure 3.4). The HPLC profiles/radio-
chromatograms generated by the two different enzymatic hydolysis procedures are illustrated in
Figure 3.5. The 3H label on the benzo(a)pyrene give the signal designated as cpm on the Y-axis.
A co-injection of the cold BPDE-dGuo and the 3H-BaP-dGuo, generated with microsomes, gave
the same UV profile at 347 nm and 254 nm and was similar to the radioactive chromatogram
(Figure 3.6) 3H-BaP-dGuo. There is a 2 minute delay between the UV-HPLC chromatogram and
the start of the radio-chromatogram. The 1s' peak at around 3.5 minutes was identified as
deoxyguanosine or undigested material. The doublet peak at 24 minutes (26 minutes on the
radio-chromatogram) is considered to be the BaP-tetrol. The doublet peak at 30 minutes (28
minutes on the radio-chromatogram) is the BaP-dGuo-adduct. These chromatograms are
reproducible. Figure 3.7 is an HPLC radio-chromatogram of 3H-dGuo-BaP after extraction and
purification via Sep-pak C 8, column. The peak at 35 minutes is considered the 3H-BPDE-dGuo
adduct. The change in retention time from 26-28 minutes to 35 minutes is due to the change in
the column temperature. The column temperature was room temperature instead of 35oC which
resulted in the peak eluting later in the chromatogram.
Figure 3.13 shows the HPLC profile of the crude mixture of the oligonucleotide (9mer)
modified with BPDE. The unmodified oligonucleotide eluted at 24 minutes. The peaks that
eluted at 42 and 44 minutes had absorbance at 347 nm and were identified as products of the
BaP-tetrol. The peak at 24 minutes corresponded to the modified nucleotide. This peak was
collected, enzymatically hydrolyzed and RP-HPLC purified. Mao et al., (1995) successfully
modified the same oligonucleotide. When using the same HPLC gradient, analyzing with a
Hypersil-ODS 5 pm column at 3 ml/min, the modified nucleotide eluted at 23-25 minutes. The
peak was collected, enzymatically hydrolyzed and HPLC purified with the gradient 0-100%
NaPhos/methanol in 60 minutes (iml/min) the modified nucleosides eluted at 49 minutes. The
unmodified nucleosides dC, dG, dT, dA eluted at 15 minutes, 20 minutes, 23 minutes and 25
minutes respectively. Following the guidelines of this experiment, the peak that eluted at 49
minutes was collected and the molecular weight was determined with electrospray-MS. However,
upon examination with electrospray-MS, these peaks did not contain BaP-dGuo.
3.3.2 Electrospray-Mass Spectral analysis of BaP-dGuo
BPDE and DNA or 2-dGuo
The BaP-dGuo adduct was RP-HPLC purified using Gradient B. The UV chromatogram
is shown in Figure 3.8. Two fractions were collected (I: 1-10 minutes, II: 20-31 minutes) into
glass pear shaped flasks. The volume was reduced and brought to 50% methanol. Samples I and
II were analyzed by Electrospray MS (Hewlett Packard). Fraction I (Figure 3.9) shows peaks at
m/z 152.1, m/z 268.2, m/z 326.2, m/z 535.2, m/z 802.2. The molecular weght of deoxyguanosine
is 267 giving a protonated m/z 268. The peaks m/z 535.2, and m/z 802.2 were dimers and trimers
of deoxyguanosine. Guanine was represented by m/z 152.1. Figure 3.10 shows the electrospray-
MS of Fraction II. The molecular weight of deoxyguanosine-benzo(a)pyrene (BaP-dGuo) is 569
giving a m/z 570 in a protonated spectrum. This ion was present in the spectrum. When this ion
was fragmented (Figure 3.11), it broke up into several peaks m/z 241.4, m/z 257.2, m/z 285.2, m/z
303.1, m/z 436.3, m/z 454.4, m/z 537.9, m/z 570.3. The peak m/z 454.4 corresponded to the loss
of the sugar. The m/z 303.1 peak was identified as the benzo(a)pyrene-diol-epoxide (mol wt.
302).
The electrospray-MS was connected to an HPLC (Hewlett Packard 1190). As the RP-
HPLC analysis progressed, the MS was analyzed for the m/z 570. Figure 3.12 shows the
electrospray-MS generated with gradient F. The appearance of four peaks demonstrated that
there were four compounds with the same molecular weight.
3.4 Conclusions
The reaction with microsomally activated 3H-BaP and calf thymus DNA successfully
yielded 3H-BaP-dGuo. The higher the specific activity of the 3H, the lower the modification level
of the DNA. It was found that the use of BPDE to modify DNA resulted in a higher yield of
BaP-dGuo adduct. The 3H-BaP-dGuo was used to determine recovery. Seventy percent of the
adduct was recovered after enzymatic hydrolysis and purification. Another 20% was lost during
I
the speedvacuum step. Therefore about 50% of the adduct was lost as it is prepared for the
acylation reaction. This was higher than the 10-15% recovery reported for fluoranthene-DNA
adducts (Gorelick, Ph.D. Thesis, M.I.T), another PAH.
There are 3 items of data that demonstrated that the BaP-dGuo adduct has been
synthesized. Benzo(a)pyrene diol-epoxide was successfully reacted with calf thymus DNA to yield
the same profile as when calf thymus DNA was modified microsomally. The HPLC profile was
the same whether the adduct was generated with BPDE or with microsomes. A co-injection of
3H-BaP adduct made by reacting 3H-BaP with calf thymus DNA and cold BPDE reacted with
cold 2-deoxyguanosine yielded the same HPLC profile. The co-injection provided 2 independent
means to monitor the adduct. UV (347nm) and the radiolabeled carcinogen 3H-BaP,
demonstrated that the profile was reproducible. As determined by electrospray-MS, the m/z 570
peak showed that the compound had the right molecular weight. The BaP-dGuo adduct
generated with microsomally activated BaP and calf-thymus DNA was used for most of the
validation experiments. In addition a protocol had been established to successfully react
benzo(a)pyrene-diol-epoxide with protected 2'-deoxyguanosine. The procedure to make the
adduct by reacting BPDE with protected 2'-deoxyguanosine was used to generate a milligram of
BaP-dGuo adduct.
Figure 3.1 Scheme to make BaP-modified deoxyguanosine
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Figure 3.2 Organic synthesis of protected BaP-dGuo
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Figure 3.3 Spectral scan of BaP-modified calf-thymus DNA
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Figure 3.4 HPLC chromatogram ofBaP-modified DNA digested to nucleosides
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Figure 3.5 HPLC chromatograms of 3H-BaP-dGuo after enzymatic hydrolysis
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Figure 3.6 HPLC chromatograms of 3H-BaP-dGuo co-injected with cold BaP-dGuo
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Figure 3.7 HPLC chromatograms of 3H-BaP-dGuo after extraction and purification
via sep-pak C 18 column
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Figure 3.8 HPLC chromatogram of BaP-dGuo
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Figure 3.9 Electrospray-MS of Fraction I: deoxyguanosine
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Figure 3.10 Electrospray-MS of Fraction II: Benzo(a)pyrene-deoxyguanosine
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Figure 3.11 Electrospray-MS Fragmentation of m/z=570 peak from Fraction II
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Figure 3.12 Electrospray-MS / HPLC analysis of BaP-dGuo
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Figure 3.13 HPLC chromatogram of oligonucleotide modified with BPDE
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Table 3.1 Summary of HPLC solvent gradients
Flow Column
Name Column Solvents A:B Gradient Rate Temp
mi/min.
A Mac Mod water:methanol linear 0-25% B in 10' 1 350C
Zorbax ODS linear 25 -80%Bin 80'
5ptm 4.5x250mm linear 80 -100% B in 10'
isocratic 100% B for 10'
B Rainin water:methanol isocratic 40% for 13' 1 350C
Microsorb C18 linear 40-60% B in 10'
5ýtm isocratic 60% B for 12'
4.5x250mm linear 60-100% B for 20'
isocratic 100% B for 25'
C Mac Mod water, pH 4.4 linear 2-20%B in 25' 1 RT
Zorbax ODS Buffered with isocratic 20% B for 15'
5ptm 4.5x250mm acetic acid linear 20-60% B in 2'
:acetonitrile isocratic 60% B for 8'
linear 60-100%B in 2'
isocratic 100% B for 16'
D Phenomenex 20mM NaPhos linear 0-100%B in 60' 3 RT
Ultramex 5 C18 pH7. 1:methanol
5pm
250 x 10mm
E Rainin 20mM NaPhos linear 0-90%B in 60' 1 RT
Microsorb C18 pH7.1 :methanol
5_im
F Phenomenex water:methanol linear 20-80%B in 80' 0.1 RT
Selectosil 5 C18 Both with 0.5% linear 80-100% B in 10'
110A 5ýtm acetic acid
150 x 1 mm
G Rainin water:methanol isocratic 60% for 10' 1 350C
Microsorb C18 linear 60-80% B in 10'
5tm linear 80-100% B in 20'
isocratic 100% B for 20'
H Mac Mod water:methanol linear 25 -80%Bin 80' 1 350C
Zorbax ODS linear 80 -100% B in 10'
5gm 4.5x250mm isocratic 100% B for 30'
Mac Mod water:methanol linear 0-25% B in 10' 1 350C
Zorbax ODS linear 25 -80%Bin 80'
5im 4.5x250mm linear 80 -100% B in 10'
isocratic 100% B for 10'
J Rainin water:methanol isocratic 7% for 20' 1 350C
Microsorb C18 linear7-20% B in 15'
5_m linear 20-100% B in 20'
Note RT= room temperature
Table 3.2 Summary of microsomal activation of BaP in the presence of calf thymus DNA
Enzymatic Modification in DNA with 3H-BaP
Exp DNA 3H-BaP Recovery of Sp. Act. Modification
# (mg) 3H-BaP(%) mCi/mmol Level
1 400 1:40,000
2 240 50 ýtCi 7 pmol (0.5) 12,500 1:700,000
3 4.5 50 pCi 88 pmol (6.3) 2,000 1:52,000
4.5 50 iCi 115 pmol (8.2) 1,000 1:38,000
4.5 50 gCi 350 pmol (20) 500 1:11,000
4.5 50 pCi 276 pmol (20) 250 1:16,000
4.5 50 pCi 160 pmol (11) 125 1:30,000
4 40 5 gCi 8 nmol 3000 1:12,000
5 2.5 mCi 833 1:28,000
Table 3.3 Modification with BaP
Substrate Form of BaP Recovery of Modification
BaP Level
CT-DNA microsomes & 1.0% 1:50,000
3H-BaP
CT-DNA microsomes & 2.0% 1:2,915
BaP
CT-DNA BPDE 2.4% 1:592
2'-dGuo BPDE 3.9% 1:563
Chapter 4 BaP-DNA Adduct Detection by Acylation With Methionine (ADAM)
4.1 Introduction
The ADAM method, introduced by our laboratory (Sheabar et. al., 1994), described the
acylation of dGuo with 35S-NHS-TBM. It was followed by a paper describing the application of
this method to measure 4-ABP-dGuo adducts. The structural analysis of the reaction products
showed that the 4-ABP-dGuo adducts can be measured by this method.
This chapter describes the further development of this method for detection of BaP-DNA
adducts. The in vitro modified calf-thymus DNA described in Chapter 3 was used to measure the
recovery and efficiency of the acylation reactions. First radioactive BaP-dGuo adduct was
incubated with non-labelled NHS-TBM. The appearance of more non-polar reaction products
made the application to measure BaP-dGuo seem feasible. The optimal conditions such as the
equivalent molar ratio, temperature, solvent and time were established experimentally.
This chapter also describes difficulties encountered when with the use of 35S-NHS-TBM.
There were many sources of contamination that interfered with quantifying the reaction products
such as poor purity of the labelling reagent, the use of Tris buffer, etc. As a result, an
improvement of the method was introduced. This involved in situ synthesis of 35S-TBM from 35S-
methionine which greatly improved the efficiency of the reaction.
The ADAM procedure (Sheabar, 1994) which subjects nucleoside adducts to acylation
with 35S- methionine was successfully used to postlabel the BaP-dGuo adduct. Figure 4.1
includes a description of the ADAM method. The top panel shows the reaction using
commercially available 35S-TBM-NHS. Since BaP-dGuo is an N2-adduct, the 3' and 5' hydroxyl
groups are both available for acylation. An improvement of the ADAM method has been the
result of using TBM for the acylation reaction instead of NHS-TBM. In addition to simplifying
the reaction, the synthesis and purification of 35S-TBM in the laboratory made it possible to
control the purity and specific activity of the 35S labeling reagent. The bottom panel of Figure 4.1
illustrates the acylation reaction involving the commercially available NHS-TBM or the in situ
synthesized TBM and the nucleoside adduct. Both reactions produced more nonpolar reaction
products that were analyzed via HPLC, because the reaction products were less polar, they eluted
later than the labeling reagent and the starting adduct material. The results of applying the
ADAM method to measure BaP-dGuo adducts are described here.
4.2 Materials
4.2.1 Chemicals
2'-deoxyguanosine and Sephadex LH-20 were purchased from Sigma Chemical Co (St.
Louis, MO). 4-aminobiphenyl (4-ABP), triethylamine (TEA) and N',N'-diisopropylcarbodiimide
(DIC), tetrahydrafuran (THF), pyridine, di-tert-butyldicarbonate, triethylamine (TEA),
dimethylfomamide (DMF) were purchased from Aldrich Chemical Co. 2'deoxy-1',2'-
[3H]guanosine 5'-triphosphate ([3H]dGTPO (31-37 Ci/mmol) were products of Amersham Co.; 35S
-Methionine (5mCi, 1000mCi/mmol) was purchased from NEN/Dupont Boston, MA). t-
butoxycarbonyl-L-methionine,N-hydroxysuccinimidyl ester,TBM-NHS was purchased from
Accurate Chemicals (Westbury, NY). t-butoxycarbonyl-L[ 35 S]-methionine,N-
hydroxysuccinimidyl ester was purchased from Boehringer-Mannheim (Indianapolis, IN)
4.2.2 Chromatography
HPLC analyses were performed on a Hewlett Packard model 1090 M liquid
chromatograph equipped with a Radiomatic flow-through radioactivity detector model A250.
(Beckman HPLC model 126 equipped with a Radiomatic flow-through radioactivity detector
model A280). Chromatographic conditions were as follows (Table 3.1): gradient B: isocratic
40% methanol/water, 13 min: linear gradient of 40-60%, 10 min; isocratic 60%, 12 min; linear
gradient of 60 to 100% methanol, 20 min; and isocratic 100% methanol, 25 min; gradient G:
isocratic 60% methanol/water, 10 min; linear gradient of 60-80%, 10 min; 80-100%, 20 min; and
isocratic 100% methanol, 20 min. Flow rate was 1 ml per min for all gradients and the column
temperature was 35oC.
4.2.3 ADAM method
Figure 4.2 describes the necessary preparation of the nucleoside adduct for the ADAM
method. The DNA must be isolated, digested to nucleosides, purified and acylated with
"S-labeling reagent. In order to isolate specific adducts of interest in a complex mixture,
immunoaffinity chromatography can be introduced at several steps, such as purification of the
nucleosides, before the acylation reaction and/or after the acylation reaction. However,
immunoaffinity chromatography was not used in these experiments for the preparation of the
BaP-adduct used for the acylation reactions. It was purified with a Sep-pak C 18 column.
4.3 Acylation of benzo(a)pyrene-deoxyguanosine with TBM-NHS
4.3.1 Acylation with unlabelled TBM-NHS
Many parameters involved in the acylation reaction can be adjusted. The main limitation is
that the adduct and solvents must be free of water. If there is water present its OH groups will
compete for the labelling reagent and the reaction will not be efficient. The components of the
reaction consist the dried adduct, nonaqueous solvent for the reaction, a base to establishe the
appropriate pH, and the labelling reagent. DIC was later added to the reaction to regenerate the
NHS-TBM. Other variables include that incubation time and temperature. The published method
dissolved the adduct in THF, used TEA as a base and determined 50,000 molar equivalents of
NHS-TBM. The reaction was incubated at 370 C for 2 hours.
Chomatographically pure 3H-BaP-dGuo adduct (270 pmole) and nonradioactive dGuo-
BaP were acylated as follows. Aliquots of dGuo-BaP and dGuo-3HBaP(pmol) were dissolved in
pyridine:THF (1:1) and acylated in the presence of TBM-NHS (50,000 molar equivalents), TEA
(1 ptl) and DIC (1 ýpl) under anhydrous conditions. After incubation for 2 hours at 370C, samples
were cooled, dried in vacuo and stored at -200 C. Samples were redissolved in 50%
methanol/water and analyzed by RP-HPLC. Three solvents, namely THF, pyridine and DMSO,
and three temperatures (room temperture, 37oC and 750C) were tried to acylate BaP-dGuo.
4.3.2 Acylation of BaP-dGuo adduct with 35S-TBM-NHS
The 35S-TBM-NHS was supplied at a specific activity of>800 Ci/mmol. The same
conditions found successful for the acylation with unlabelled TBM-NHS were used for acylation
of 5 pmole of the same adduct with 35S-TBM-NHS ester. A molar equivalent of 400,000 was
maintained for the reactions and the adduct was dissolved in pyridine. The mixture was incubated
at 37oC for 2 hours.
After the acylation reaction, a solvent extraction clean-up step (Figure 4.3) was necessary
to remove contaminants that could hide the signal given by the reaction products. Samples
acylated with 35S-labeling reagent were reconstituted in 50 pl methanol (2 times), 20 pl1 methanol,
250 ptl H20 (2 times) and transferred into 15 ml polypropylene tubes. The samples were then
extracted 7 times with 3 ml of toluene. The toluene layer was discarded and the remaining
aqueous portion was transferred to a 600 p1l tube. The volume was reduced via rotary
evaporation for 15-30 minutes and analyzed by HPLC. Hexane was later used, instead of toluene,
as a solvent to clean up the reaction product contaminants. The recovery of the adducts through
this process was determined for [3H]dGuo, 8-oxo-[3H]dGuo, [3H]dGuo-4ABP and [3H]BaP-
dGuo. Since the purity of the 35S-labelling reagent could not be guaranteed to be more than 40%
pure, often contaminants that were present obscured the signal that would be used to detect the
carcinogen. A Sep-pak step was added after the solvent extraction step.
In order to determine the signal to noise ratio, 7.5 pmol of 3H-BaP-dGuo was acylated
with 35S-TBM-NHS (3.1 mCi/mmol). A molar ratio of labelling reagent was 400,000 times the
amount of adduct. Each reaction mixture was incubated for 37oC for 2 hours, extracted with
either toluene or hexane and analyzed by RP-HPLC, using gradient H.
4.3.3 Results and discussion
Several variables of reaction conditions were modified, including solvent, amount of base,
amount of labelling reagent, temperature, and length of incubation time. The incubation at 750 C
resulted in the degradation of the BaP-adduct, while incubation at 370 C worked very well. The
BaP-dGuo adduct did not dissolve completely in THF, but went into solution quickly with
pyridine. However, the TBM-NHS required the addition of THF in the reaction to be completely
dissolved. Figure 4.4 illustrates the successful acylation of BaP-dGuo with TBM-NHS. The top
panel shows the reaction with the adduct dissolved in pyridine and incubated with TEA and DIC,
but no TBM-NHS. The bottom panel shows the same reaction, but incubated in the presence of
TBM-NHS (molar ratio 1:400,000).
The 35S-TBM-NHS reaction products co-elute with the 3H-BaP-dGuo adduct reaction
products at 96 and 98 minutes (Figure 4.5). This is strong evidence to support the interpretation
that the later appearing peaks were the expected reaction products: Figure 4.6 illustrates
35S-TBM-NHS incubated in the presence of 5 pmol of 3H-BaP-dGuo adduct (panel A) and
incuabated alone (panel B). The peaks present in the 95 minute to 100 minute region were
acylated products. When the amount of 3H-BaP-dGuo adduct was increased (0.2 pmole-5pmole),
the amount of 35S-acylated products increased linearly (Figure 4.6, panel C). Figure 4.7 and 4.8
show the HPLC chromatograms of the 35S-TBM-NHS reagent control (no adduct in the mixture)
and the reaction mixture in the presence of the adduct. In both cases, the addition of the adduct
to the mixture resulted in the appearance of later appearing peaks. The extraction with the
toluene is easier than the extraction with hexane followed by Sep-pak procedure. But the amount
of acylation products lost during the clean up step was also examined. Table 4.1 shows the
recovery of the different adducts during the solvent extraction process after being acylated with
TBM-NHS. The toluene extraction resulted in more of the acylation products being lost (16%)
versus only 3% lost in the hexane extraction clean-up step.
The signal to noise ratio is summarized in Table 4.2. The acylated reaction products
appear in the region of 95-100 minutes. The background 35S radioactivity was determined for the
region of 85-90 minutes. In the case where no adduct was added to the reaction, the background
35S radioactivity ranged from 29,264 to 41,560 cpm. The radioactivity present in the region,
where acylated products would appear, ranged from 28,776 to 49,504. The average net 35S
radioactivity was 2828cpm. In the case where the acylation products of the adduct were toluene
extracted, the net 35S radioactivity was 25,406 cpm and 48,820 cpm (,=37,113). The net cpm of
the adduct acylation products after hexane extraction were in the same range (40,920 cpm and
53,616 cpm; 5=47,268). The signal is at least one order of magnitude above the background 35S
noise.
Optimal reaction conditions were as follows: The temperature of 37oC and incubation for
2 hours was used for the rest of the reactions. The reaction mixture did not require TEA, so it
was eliminated as the reaction condition requirement. DIC was needed to enhance the reaction.
The labelling reagent was dissolved in THF and the reaction mixture maintained a 1:1
THF:pyridine ratio. The amount of molar equivalents needed for the reaction was also examined.
The acylation reaction plateaued at 50,000 molar equivalents; therefore, the use of 400,000 was
not necessary and when analyzing human samples would greatly decrease the specific activity and
as a result, the sensitivity would be greatly comprimised. In addition, it was extremely difficult to
get the entire sample into solution for HPLC analysis. As a result 50,000 molar equivalents were
used in all further reactions.
4.4 Acylation of benzo(a)pyrene with TBM
An improvement of the ADAM method has been the result of using TBM for the acylation
reaction instead of NHS-TBM. In addition to simplifying the reaction, the synthesis and
purification of 35S-TBM in the laboratory made it possible to control the purity and specific
activity of the 35S labeling reagent. Figure 4.1 illustrates the acylation reaction involving the
commercially available NHS-TBM or the laboratory synthesized TBM and the nucleoside adduct.
Both reactions produce in more nonpolar reaction products which can be analyzed via HPLC.
4.4.1 Synthesis of 35S-TBM
The protection reaction of 35S-methionine was performed as follows (Figure 4.9):
35S-methionine (5mCi, 1000Ci/mmol) was thawed and transferred to a 5 ml glass tube. The
solution was evaporated dry (2-3 hours) and kept on dry ice. Di-tert-butoxy-dicarbonate (5 tl),
DMF (50ptl), TEA (1 tl) were added the mixture and incubated for 15 minutes at room
temperature. Purity and radioactivity determination were determined from an aliquot (1 ml) was
removed from the mixture and added to 5 ml H20. The reaction mixture was evaporated (70
minutes), redissolved in 2 ml methanol and 200 ml H20 and further purified via HPLC. Fraction 2
was collected and concentrated. The H20:methanol HPLC gradient (gradient J) used for purity
analysis and purification is was 7% MeOH isocratic for 20 minutes, isocratic 20% meOH for 15
minutes, linear gradient to 100% over 20 minutes.
4.4.2 Acylation of BaP-dGuo with 35S-TBM
Cold BaP-dGuo adducts (2 nmol), dissolved in a mixture of pyridine:THF, was reacted
with 35S-TBM (1000 Ci/mmol) for 2 hours at 370C. The reaction mixture was cooled, vacuum
dried and the samples were incubated for an additional 30 minutes, 37°C before being stored at
-20'C. The reaction products were hexane extracted and analyzed via RP-HPLC.
After the acylation reaction, a solvent extraction clean-up step is necessary to remove
contaminants that would hide the signal given by the reaction products. Samples acylated with
35S-labeling reagent were reconstituted in 50 ml methanol (2 times), 20 ml methanol, plus 250 ml
H20 (2 times) into 15ml polypropylene tubes. The samples were then extracted 7 times with 3ml
of hexane. The hexane layer was discarded and the remaining aqueous portion was transferred to
a 600 ml tube. The volume was reduced via rotary evaporation for 15-30 minutes and analyzed
by HPLC.
A radio-chromatogram, via the on-line radioactivity detector and the UV chromatogram,
via the diode array detector were generated simultaneously (Figure 4.10). The acylation products
as determined by absorbance at 347nm and 35S both co-elute at 58-60 minutes. This provided
additional evidence that the reaction was producing acylated BaP-dGuo adduct.
To further investigate the acylation reaction of BaP-dGuo with TBM, various amounts
(fmole-pmole) 3H-BaP-dGuo were dried and reacted with in situ synthesized and purified
35S-TBM. The specific activities ranged from 0.4mCi-1000Ci/mmol). The ratio for the sample
with the most adduct was calculated. The 35S-TBM was prepared and 10ld of the mixture was
added to each sample already dissolved in pyridine:THF. The samples were incubated at 37oC for
2 hours. The reaction mixture was cooled, vacuum dried and the samples were incubated for an
additional 30 at 370 C before being stored at -200C.
4.5 Results and discussion
A reproducible linear response was observed between the amount of substrate
(3H-BaP-dGuo) and the area of 35S peaks (95 minutes-100 minutes). The ratio of 1:400,000 was
used for the 2 different specific activities. Various amounts of dried 3H-BaP-dGuo (0 fmol, 5
fmol, 10 fmol, 20 fmnol, 50 fmol, 100 fmol and 1000 fmol) were reacted with 35S-TBM at a
specific activity of 1000 Ci/mmol. This produced a linear response (R=0.9279). This linear
response was reproduced (R=0.860) using different amounts of 3H-BaP-dGuo i.e., 50 fmol, 100
fmnol, 200 fmol, 500 fmol and 1000 fmol, and a specific activity of 10 Ci/mmol. (Figure 4.11).
These results demonstrated a linear and highly significant correlation between the amount of
adduct reacted and total 35S radioactivity detected in the acylated products.
Recently, the cleanup procedure, performed after the acylation reaction, was
abandoned. HPLC purification of the 35S-TBM, prior to acylation, seemed to be adequate for
detection of carcinogen-adducts. The acylation reaction of the BaP-dGuo standard made with
protected 2'-dGuo is shown in Figure 4.11. The acylation products eluted at the same retention
time as the acylation products of the standard made with calf-thymus DNA.
4.6 Conclusions
It was demonstrated that incubation of chomatographically pure 3H-BaP-dGuo adduct
(270 pmole), dissolved in pyridine:THF (50:50), in the presence of unlabeled TBM-NHS
(1:50,000) for 2 hours at 370C and analyzed by RP-HPLC produced reaction products at a 70%
efficiency. The peaks between 55 minutes-60 minutes co-eluted in both the liquid chromatogram
and the radio-chromatogram. The reaction products co-eluted with those obtained by acylating 5
pmol of 3H-BaP-dGuo with 35S-TBM-NHS. In addition there was a linear correlation between
the amount of 3H-BaP-dGuo used for the reaction and the area of the 35S-acylated products.
Specific activities of 35S-TBM-NHS from 0.4 mCi/mmol to 10 Ci/mmol to 1000 Ci/mmol were
found to be successful. The use of hexane or toluene, after acylation with 35S-TBM-NHS proved
useful to get rid of contaminants that would interfere with the detection of the acylation products.
35S-TBM can be synthesized and purified in our laboratory. A linear relationship was
observed between the amount of adduct versus the amount of 35S acylated products when 3H-BaP
was reacted with 35S-TBM. The acylation of BaP-dGuo was successful. Now that the purity of
the reagent can be controlled, the solvent extraction performed after acylation is no longer
necessary.
Figure 4.1 Description of Adduct Detection by Acylation with Methionine (ADAM)
Top panel: Reaction with commercially available 35S-TBM-NHS
Bottom Panel: Reaction with 35S-TBM synthesized from methionine
Figure 4.2 Flow diagram for carcinogen-nucleoside labelling with ADAM
Figure 4.3 Flow diagram for solvent extraction of acylated products
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Figure 4.4 Acylation of BaP with unlabelled TBM-NHS
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Figure 4.5 Co-elution of reaction products after acylation of BaP-dGuo with TBM-NHS
1.30 x 10 4
cpm
0.00
35S/
40.00 50.00 60.00 70.00 80.00 90.00 100.00 \110.00
time (min) 3H
Top line: BaP-dGuo acylated with 3 5S-TBM-NHS
Bottom line: 3H-BaP-dGuo acylated with unlabelled TBM-NHS
Figure 4.6 Acylation of BaP-dGuo with 35S-TBM-NHS
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Figure 4.7 HPLC chromatogram ofBaP-dGuo acylated with "S-TBM-NHS after
toluene extraction
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Figure 4.8 HPLC chromatogram of BaP-dGuo acylated with 35S-TBM-NHS after
hexane extraction and Sep-pak purification
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Figure 4.9 In situ synthesis of 35S-TBM
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Figure 4. 10 HPLC chromatogram of BaP-dGuo acylated with 3 5S-TBM
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Table 4.1 Recovery of adducts during solvent extraction after acylation with 35S-TBM-NHS
Acylation Products Lost during Extraction (%)
PH]dGuo 8-Oxo-[3H]dGuo PH]dGuo-8-ABP dGuo-2-PH]BaP
36.1
27.2
27.8
Toluene 13.2
12.3
41.3
15.8
26.3±11.8 18.4±3.7
58.5
84.2
26.9
45.8
90.3
51.9
76.2
62.0122.7
18.9
13.9
16.4±3.5
1.6 N.D. 10.4 3.2
1 11.6 3.2
1.4 6.3
0.9 3
Hexane 1.8 3.8
2.3
6.8
7.2
1.3±4.4 6.4±3.4 3.2±0
Table 4.2 Signal to noise ratio
35S acylated products: Toluene vs. Hexane Extraction
Adduct Solvent Signal 95'-100' Noise 85'-90' Net Cpm
none hexane 41,184 41,560 -376
none hexane 49,504 41,408 8,096
none toluene 28,776 29,264 -488
none toluene 34,112 30,032 4,080
7.5 pmol toluene 96,900 48,080 4,8820
7.5 pmol toluene 64,936 39,520 25,406
7.5 pmol hexane 109,360 55,744 53,616
7.5 pmol hexane 100,208 59,288 40,920
Chapter 5. DNA Adducts of Benzo(a)pyrene: Animal Studies
5.1 Introduction
Since BaP is an animal carcinogen, mice were treated with BaP, to test the
applicability of the ADAM method to BaP-DNA adducts formed in living tissues. The
optimal acylation conditions for the analysis of BaP-dGuo were determined with in vitro-
modified calf thymus DNA. The molar ratio needed to obtain the best reaction efficiency was
1:50,000, incubated at 370 C for 2 hours. These reaction conditions were to be used for in
vivo samples.
This chapter describes two animal experiments. In the first experiment, mice were
given a large dose of highly radioactive benzo(a)pyrene and the samples were taken 24 hours
later. The use of radioactivity (3H) provided an independent means to monitor the recovery of
the BaP-dGuo throughout the process of DNA isolation up to the acylation products. In
addition, a radio-chromatogram was generated from the 3H-BaP given to the animals. The
second purpose of this experiment was to determine if DNA could be isolated from paraffin
embedded tissues. Most studies which used postlabelling procedures analyzed fresh or frozen
tissue. Many pathology laboratories store tissue biopsies embedded in paraffin. Goelz (1995)
showed that DNA can be isolated from wax-embedded tissues and used to detect point
mutations in specific genes. It would be valuable to use the vast resource of archival material
to detect the presence of carcinogen-DNA adduct to obtain evidence of past exposure. 32p_
postlabelling analysis of fixed tissues was carried out in rats treated with BaP and AAF
(Hewer and Phillips,1993). The adduct levels were shown to be stable even in tissues fixed
for 92 days and then embedded. In pathology laboratories, the time of fixation can be
indefinite. In the experiment reported here, the livers from the animals were divided into 4
sections. One section was frozen the other 3 sections were fixed in 10% formalin for 3
different time periods. The chromatography and acylation results are reported here. The
amount of 35S incorporated in authentic 3H-BaP-DNA adduct samples were used for the
calibration and quantification of the BaP-DNA adduct levels in both the frozen and embedded
tissues.
The purpose of the second experiment was to analyze BaP-DNA adducts in mice that
were treated before being weaned with a dose of BaP that will cause tumors. The newborn
mouse lung adenoma assay (Busby, 1984) was used for 3 reasons: (1) The assay has proven to
successfully produce tumors in mice treated with polycyclic aromatic hydrocarbons; (2) The
results can be seen within a short period of time. Lung tumors appear within 6 months; (3)
Adduct levels can be compared with tumor frequency. The target tissues in this assay are the
lungs (primary) and liver (secondary). Previous results (Busby, unpublished) involving the
tumorigenicity of BaP showed that a total dose of 210 jtg produced 3.85 lung tumors/mouse
and 28% liver tumors in males. The total dose of 150 pg produced -2 lung tumors/mouse. In
this study, lung tumors were produced in all of the male litters. The DNA was isolated from
the tissues. The ADAM method was used to determine the level of modification in the lungs
and livers and are recorded here.
Chemicals
Benzo(a)pyrene was obtained from Aldrich Chemical Company (Milwaukee, WI).
Rat liver cytosol was prepared from postmitochondrial supernatant fractions (SL-9) supplied
by Molecular Toxicology, Inc. (Annapolis, MD). 3H-BaP was purchased from Amersham
Corporation (Arlington Heights, IL). anti-benzo(a)pyrene-r-7, t-8-dihydrodiol-t-9,
10-epoxide (±) was purchased from NCI Chemical Carcinogen Reference Standard
Repository (Frederick, MD). Dimethylsulfoxide (DMSO) was purchased from Burdick and
Jackson Laboratories, Inc. (Muskegon, MI) and stored under argon. 35S -Methionine (5mCi,
1000mCi/mmol) was purchased from New England Nuclear Products/Dupont (Boston, MA).
t-butoxycarbonyl-L-methionine, N-hydroxysuccinimidyl ester, TBM-NHS was purchased from
Accurate Chemicals (Westbury, NY). Sep-pak C 18 environmental cartridge were obtained
from Waters (Milton, MA). Nuclease P1 (NP, from Penicillium citrinum) was purchased from
Sigma Chemical Company (St. Louis, MO). Snake venom phosphodiesterase from ICN
Pharmaceuticals (Costa Mesa, CA ). Proteinase K (from Tritirachium album), Rnase A and
Alkaline Phosphatase from calf intestine were purchased from Boerhinger Mannheim
Biochemicals (Indianapolis, IN). Flo-Scint III scintillation fluid was purchased from Packard
Instrument Company (Downers Grove, IL). N', N',-diisopropylcarbodiimide was obtained
from Aldrich. An LKB Liquid Scintillation Counter was used (Turku, Finland). Solvents
used were HPLC grade.
5.2 Short term dosing/ Acute Exposure
5.2.1 Animal Treatment
Forty-eight female CD-i mice (6-8 weeks old) from the Charles River Laboratory,
Wilmington, MA were housed in metabolic cages, 6 per cage. Food and water were given ad
libitum and animals were housed in 12-h dark cycle for 24 h. Mice were each injected i.p.
with 3H-BaP (24 mg/kg b.w., 117.04 mCi/mmole) dissolved DMSO (100ll) or solvent only.
Animals were sacrificed 24 hours later. The livers were collected and washed with RSB
buffer and divided into 4 parts. 1 part was frozen in liquid nitrogen and stored at -1000C. The
remaining 3 parts were fixed and embedded in paraffin.
5.2.2 Fixation and embedding of liver samples
The remaining 3 parts of liver from each animal were put in fixative cassettes. One of
each was fixed in 10% formalin for 24, 48 and 168 hours before embedding in paraffin. Prior
to embedding the tissues in paraffin, the tissues were processed for 15 hours in preservatives
using an automatic tissue processor (Tipshaw, Trimatic Model 2500, Detroit, MI). They were
then positioned into blocks of paraffin and stored. The samples of a given fixation time were
process simultaneously.
5.2.3 Deparaffinization of liver tissues
The excess paraffin was removed with a razorblade. The samples were cut into 5
pieces and transferred into new cassettes, tightly closed and placed into an erlenmeyer flask.
Xylene (200 ml) was added and the erlenmeyer was placed under vacuum and immersed in a
water bath at 470C for 45 minutes. The xylene was discarded and the process was repeated
for an additional 45 minutes. Cassettes were then successively soaked twice in 100%, 95%,
and 75% ethyl alcohol and water for 5 minutes. Samples were stored at -200 C until ready for
DNA isolation.
5.2.4 DNA isolation
DNA was isolated from the livers according to the method of Davis et al (1986).
Briefly, the homogenates were incubated with proteinase K at 370 C, extracted with
phenol:chloroform:isoamyl alcohol. The DNA was ethanol precipitated and dissolved in SSC
buffer (5.4 mM trisodiumacetate, 30mM NaCl). The DNA was treated with DNase free-
RNase for 30 minutes at 370 C. The DNA was extracted with phenol:choroform, ethanol
precipitated, washed with 70% ethanol, dried and dissolved in 1 ml 10mM Tris buffer (pH
7.4) and stored at 40C overnight. DNA concentration was determined by UV absorbance.
The ratios of A 260nm/A 280nm ranged from 1.83-1.90. The DNA was then enzymatically
hydrolyzed as described previously.
5.2.5 Enzymatic hydrolysis of DNA
DNA samples were hydrolyzed to mononucleosides using NP,, snake venom
phosphodiesterase and alkaline phosphatase. 200ptg DNA in 0.1 M sodium acetate buffer
were hydrolyzed with NP, (84.5 units NP,/mg DNA) for one hour at 37oC. Snake venom
phosphodiesterase (0.9 SVPD units/mg DNA) and alkaline phosphatase (16.7 units AP/mg
DNA) were then added and the incubation was continued at 370 C for one hour.
5.2.6 Purification of enzymatic digests
The enzymatic hydrolysates were loaded onto a C18 Sep-Pak cartridge,
preconditioned with methanol (20ml) and water (20 ml), and recycled through 4 more times.
The column was washed with water (20 ml) and the modified nucleosides were eluted with
methanol (20 ml). The solvent was removed in vacuo. The nucleosides were redissolved in
40% methanol H20 (vol/vol), passed through Millipore cellulose filters (nominal molecular
weight limit 30,000) and stored desiccated at -200C. Samples were then acylated with 35S-
TBM-NHS and/or analyzed by RP-HPLC.
5.2.7 HPLC analysis
HPLC analyses of BaP adducts from calf thymus DNA modified under in vitro
conditions and from mouse liver DNA were performed on a Hewlett Packard (model 1090 M)
liquid chromatograph equipped with a Radiomatic Flo-One (Meriden) flow-through
radioactivity detector (model A250). A Microsorb 5pt C, 8 column was used with the
following gradients with a 1 ml/min flow rate at 350 C: Gradient I: linear gradient of 0-25%
methanol/water, 10 minutes; linear gradient of 25%-80%, 80 minutes; linear gradient of 80-
100% methanol, 10 minutes; and isocratic 100% methanol, 10 minutes. 35S-acylation
products were analyzed by RP-HPLC with the same conditions as above, using the following
gradient. Gradient B: isocratic 40% methanol/water, 13 minutes: linear gradient of 40-60%
10 minutes; isocratic 60%, 12 minutes; linear gradient or 60-100% methanol, 20 minutes; and
isocratic 100% methanol 25 minutes.
5.2.8 Acylation with 35S-TBM-NHS
Liver samples were acylated according to the method described by Sheabar (1994).
3H-BaP-dGuo adduct samples (5 pmol) were prepared as mentioned above from in vitro
modified calf thymus DNA and liver tissues were acylated with 35S-TBM-NHS. Purified
DNA of control animals were also spiked with adduct from DNA modified under in vitro
conditions and acylated. Acylation was carried out for 2 hours at 37oC in the presence of 35S-
TBM-NHS ester (50,000 mol-equivalents) in THF (50 ptl), pyridine (50 p•), DIC (1 tl). Liver
DNA samples isolated from animals treated with DMSO only and containing amounts of
adduct equivalent to those used in the acylation were similarly treated and acylated.
Following the acylation, samples were dried under reduced pressure for 30 minutes,
redissolved in methanol (100 pl1) and water (500 tl), purified by extraction from hexane (5 x 5
ml) and analyzed by HPLC, using gradient B.
5.3 Results And Discussion
5.3.1 Chromatography
The isolated DNA from 6 mice were pooled to generate a HPLC profile of the 3H-
BaP-DNA (Figure 5.2) using Gradient I. Sixty-seven percent of 3H-BaP-DNA adducts were
recovered from the enzymatic hydrolysate of the DNA after chromatography by C18 sep-pak
cartridges. The major HPLC peak eluted at 52 minutes. The HPLC profiles of digests of
BaP-DNA samples isolated from tissues fixed for 0-168 hours differ from that of frozen tissue
(Figure 5.2). A new peak appeared at 8 minutes after fixation for more than 24 hours. The
acid hydrolysis of this peak (0. 1N HC1, 6 hours, 80oC) reveals the appearance of new peaks
(using Gradient A) at 24, 38 and 64 minutes. The peak detected from the enzymatic digestion
of calf thymus DNA modified under in vitro conditions were different from these retention
times. This suggests that the peak that appears at 8 minutes represents undigested
oligonucleotide. It appears that the the efficiency of enymatic digestion was affected by length
of fixation. On the contrary, Hewer and Phillips (1993) used gel electrophoresis to examine
the completion of enzymatic digestion in tissues fixed in formalin for 0-92 days and found that
the enzymatic hydrolysis was not affected by the fixation in formalin.
5.3.2 Adduct Levels
Samples acylated by 35S-TBM-NHS were analyzed by RP-HPLC. It revealed a peak
at 52 minutes. Figure 5.3 shows the radio-chromatograms of samples acylated by 35S-TBM-
NHS. The peaks at 50 minutes and 55 minutes displayed in the radio-chromatogram of the
treated mouse samples do not appear in the reagent control (Figure 5.3a) or the DMSO
control mice (Figure 5.3b). When the DMSO control sample is spiked with the internal 3H-
BaP-dGuo internal standard (Figure 5.3c) before acylation, the peaks have the same retention
time as the BaP treated mouse sample (Figure 5.3d).
The modification levels were found to increase significantly with increase in the length
of fixation and reached a plateau after >48 hours of fixation. (data not shown). The results of
the modification levels (Table 5.1) were calculated on the basis of the radio-labeled 3H-BaP
and with the amount of 35S incorporated into the acylation products. There was a good
correlation between the modification levels regardless of whether calculations were based on
3H or 35S. Although the modification level looked like it increased by 20-fold after fixation
for 168 hours, the amount of picomole of BaP based on the internal standard was found to be
< 5 pmole. Therefore, the calculation of total nucleotides is incorrect. There appears to be a
selection ofBaP-modified DNA that occurs during the isolation, hydrolysis, purification and
acylation of DNA from formalin-fixed paraffin embedded tissues. If the numbers were taken
at face value, it would give a inflated impression of the modification level. The inflated
numbers are due to the loss of, or inability to recover unmodified DNA. One explanation
could be that the crosslinking of the proteins in the DNA (ex. histones) is virtually irreversible
making it extremely difficult to isolate and digest unmodified DNA. Therefore, when
computing modification levels in fixed-embedded tissues, from other animal samples or human
samples, the numbers of BaP adducts/ 108 nt should be divided by 20.
5.4 Newborn Mouse Lung Adenoma Assay
5.4.1 Animal Treatment
Pregnant CD-1 mice obtained from Charles River Breeding Laboratory (Kingston,
NY) approximately 7 days before the end of gestation were housed individually in
polycarbonate cages equipped with dust filters and contained hardwood chip bedding
(Sani-Chips; P.J. Murphy Co., Moonachie, NJ) in laminar airflow isolation cubicles under
controlled temperature (22+1oC), light (12h light-dark cycle) and humidity (50+10%). NIH
open formula diet (NIH-07 Rat and Mouse Feed; Zeigler Bros, Inc., Garners, PA) and
distilled water were supplied ad libitum.
Animals were dosed with benzo(a)pyrene as previously described with a dose of 210
gg benzo(a)pyrene /35 ýd DMSO three times over a two week period (Figure 5.4) Freshly
prepared preparations of BaP dissolved in DMSO were protected from light until
administration to animals. Newborn mice were injected i.p. on day 1 with 5 ml DMSO
containing 1/7 of the total dose, followed by a second treatment on day 8 containing 2/7 of the
dose dissolved in 10 ld DMSO, and the third treatment on day 15 with the remaining 4/7 of
the dose dissolved in 20 gl DMSO. 3H-benzo(a)pyrene (240 mCi/mole) was used for two
reasons: (1) provide a means of determining modification level and following recovery and
(2) provide an independent means of verification for carcinogen detection by postlabeling
methods. Control mice were given DMSO in the same volumes. At least 50 animals were
included in each treatment group. Tissues for DNA adduct analysis were collected from
animals sacrificed by decapitation at 24 hours, 72 hours, 1 week, and 5.5 months after the last
injection. Lungs, livers, and kidneys were quickly excised and rinsed in IX RSB (10mM
Tris-HC1, pH 7.4, 10 mM NaCI and 25 mM Na2EDTA, pH 7.4). After blotting dry, organs
were individually frozen in liquid nitrogen and pooled in polyethylene scintillation vials in dry
ice according to tissue, sex and litter. The tissues were stored in polyethylene vials at -100 0 C
until DNA could be isolated.
5.4.2 Isolation of DNA
DNA was isolated as follows. Pooled tissues (<0.400g) were homogenized with a
motor driven Polytron in 19ml of lysis buffer (800 mM GuHC1, 20 mM EDTA, 30mM
Tris/HCl, 5% Tween-20, 0.5% Triton X-100, pH 8.0) containing RNase A (200 ptg/ml). The
homogenate was digested with Proteinase K (1mg/ml) at 500 C for 2 hours or until clear.
Unclear lysates were centrifuged 1,500 g for 10 minutes. The clear lysate was loaded on to a
Qiagen genomic-tip-500/G anion exchange column (Qiagen Inc. Chatsworth, CA). After
washing twice with 15 ml of wash buffer (1.0 M NaCl, 50 mM MOPS, 15% ethanol, pH 7.0),
the DNA was eluted with 15ml of 1.25 M NaC1, 50mM Tris/HCl, 15% ethanol, pH 8.5). The
DNA was precipitated with 0.8 volume of isopropanol and centrifuged (3,000 g for 1 hour).
The pellet was washed twice with 1 ml of ice-cold 70% ethanol, air dried and dissolved in
water. DNA purity was determined by the A260nm/A 280nm ratio and the concentration was
calculated by absorbance assuming an O.D. of 1.0 equal to 50 [g/ml DNA. DNA that did
not have a A 26 0 nm/A 2 80 nm ratio of at least 1.7, was and retreated with proteinase K at 500 C
overnight, then dissolved in 750mM NaCl, 50 mM 3-(N-morpholino)-propanesulfonic acid
(MOPS), 15% ethanol) and purified with as previously using a Qiagen genomic-tip-500/G.
5.4.3 Enzymatic hydrolysis of DNA
DNA samples were hydrolyzed to mononucleosides using NP,, snake venom
phosphodiesterase and alkaline phosphatase. 200ýtg DNA in 0.1 M sodium acetate buffer
were hydrolyzed with NP1 (84.5 units NP,/mg DNA) for 3 hours at 370 C. Snake venom
phosphodiesterase (0.9 SVPD units/mg DNA) and alkaline phosphatase (16.7 units AP/mg
DNA) were then added and the incubation was continued at 370C for 3 hours.
5.4.4 Immunoaffinity chromatography
Immunoaffinity chromatography of BaP DNA adducts from preweanling mice:
Hydrolyzed DNA was separated into modified and unmodified nucleosides via immunoaffinity
chromatography. 200pl columns were poured using immobilized 8E-11 antibodies.
Hydrolysate was recycled through the column 3 times, washed with 5ml of water (25 column
volumes) and modified nucleosides were eluted with 2ml of methanol (10 column volumes).
The volume was divided into triplicate samples in amber 500 ml polypropylene tubes (VWR)
and dried in vacuo.
5.4.5 Manufacturing of 35S-TBM
The protection reaction of 35S-methionine was performed as follows: 35S-methionine
(5mCi, 1000Ci/mmol) was thawed and transferred to a 5ml glass tube. The solution was
evaporated dry (2-3 hours) and kept on dry ice. Di-tert-butoxy-dicarbonate (5 p•), DMF (50
pl), TEA (1 p1) were added the mixture and incubated for 15 minutes at room temperature.
Purity and radioactivity were determined from an aliquot (1 p1) which was removed from the
mixture and added to 5 ml H20. The reaction mixture was evaporated (70 minutes),
redissolved in 200 pl methanol and 200 pl H20 and further purified via HPLC. The
water:methanol HPLC gradient (gradient J) used for purity analysis and purification was: 7%
meOH isocratic for 20 minutes, isocratic 20% meOH for 15 minutes, linear gradient to 100%
over 20 minutes.
5.4.6 Acylation of DNA from mouse samples with 35S-TBM
The dried samples were resuspended in pyridine containing TBM (5x1 04 molar
equivalents) and DIC (ratio of 1:16, TBM:DIC) and the mixture was incubated for 2 hours at
37oC. Similar conditions were used to acylate dGuo-3H-BaP isolated from calf thymus DNA
adducted in vitro and synthesized dGuo-BaP standard. The samples were dried under
reduced pressure and stored at -200C until analysis. The samples were resuspended and
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analyzed via RP-HPLC. The water:methanol gradient (Gradient B) used was isocratic 40%
methanol for 13 minutes, linear gradient of 40-60% methanol for 10 minutes, isocratic at 60%
for 12 minutes, linear gradient of 40-60% for 20 minutes, and isocratic 100% for 25 minutes.
5.5 Results and Discussion
5.5.1 Tumor Incidence
The purpose of this experiment was to test the applicability of the ADAM method to
BaP-DNA adducts formed in living tissues. The newborn mouse lung adenoma assay
successfully produced tumors in mice treated with the total dose of 150 pýg of BaP. The total
number of animals that developed at least one lung tumor (top panel) or liver tumor (bottom
panel) 5.5 months after dose of210 pg BAP are displayed in Table 5.2. No liver tumors were
detected in the female mice. Tables 5.3 & 5.4 display the tumor frequency resulting from the
newborn mouse assay. The tumor range for the male mice (Table 5.3) was 3-29
tumors/animal and 0-5 liver tumors/animal. The female mice (Table 5.4) displayed a tumor
range of 0-5 lung tumors/animal and there were no liver tumors detected. This difference in
the tumor frequency, although the dose was the same may be attributed to litter variance in
the formation of tumors.
5.5.2 Adduct Levels
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Since the tumor incidence in the male mice, the male samples were acylated. The
DNA (200ptg) was isolated from the lung and liver tissues. After the DNA was extracted
from the tissues enzymatically hydrolyzed and immuno-affinity purified, the samples were
acylated. A positive control, 100fmole of BaP modified calf thymus DNA was run along side
of the samples. Figure 5.5 displays a representative chromatogram of an acylated mouse
sample. The top panel is the DMSO control sample. The bottom panel displays the acylation
of a lung sample from a 72 hour treated mouse. The region from 55-60' was determined after
the subtraction of the paired DMSO control. The amount of BaP present was calculated
based on the radioactivity of the positive control. Conversion of molar amounts of adducts to
DNA modification level assumed an average molecular weight of 324 per nucleotide. The
levels and persistence of the BaP-DNA adducts in the male mice is shown in Figure 5.6. BaP-
dGuo adducts persisted at detectable levels in the DNA from the tissues. Maximum adducts
in the lungs were found 165 days post-treatment. The maximum levels in the livers occurred
three days post-treatment. By 165 days following treatment, BaP-dGuo adducts decreased in
the liver 9.3%. The phenomenon of PAH adduct levels reaching maximum levels at 3 days
was also described by Wang et al., (1995). The same dosing regimen was used for
fluoranthene. The anti-FADE adducts reached maximum levels after 3 day in lungs, livers,
spleen/thymus and kidney. The lung had 0.5 fmole/pg DNA. The liver and kidneys had 0.13
frnole/gg DNA. In a similar study, (Melikian, et al., 1989), where the metabolism of 3H-BaP
in newborn mice was studied, the levels of organic soluble radioactive metabolites reached
maximum levels at day 2 for the lung and day 4 for the liver. The maximum levels reached
after 3 days possible reflect the saturation of the capacity of newborn mice to absorb,
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transport, metabolize and eliminate the large dose of PAH administered and also to remove
the DNA adducts formed through metabolic activation of the PAH (Wang et al., 1995).
5.6. Conclusions
The levels of BaP-DNA adducts were investigated in treated mice. The 24 hour
exposure to 3H-BaP revealed the applicability of the ADAM method to in vivo samples and
the correlation of the adduct levels based on 3H and 35S validated the method. It was
demonstrated that DNA can be isolated from paraffin embedded tissues and analyzed for
BaP-dGuo adducts. Adduct levels of BaP isolated from fixed-embedded tissues must be
divided by 20 to correct for the nucleotide levels.
The use of 210 g BaP in the newborn mouse lung adenoma assay successfully
produced tumors. Samples were collected for analysis of BaP-DNA adducts in lungs and
livers. The persistence of adduct levels in mice dosed in the newborn mouse assay was
determined by the ADAM method.
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Figure 5.1 Protocol for 24 hr exposure of mice to3H-BaP
Treated 48 mice with 3H-BaP
5 mg (2.5 mCi/mmol)
Sacrificed after 24 hr
Divided liver into 4 parts
J
Froze tissue Fixed tissue in 10% formalin
for 24 hr, 48 hr, 168 hr
Embedded in paraffin
Deparaffinized
Isolated DNA
Purified enzymatic digest
Determined 3H-BaP modification levelDetermined 3H-BaP modification level
Acylated 5 pmole Pooled 6 animals
HPLC HPLC
Figure 5.2 HPLC radio-chromatogram of 3H-BaP-DNA adducts
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Figure 5.3 HPLC profiles of mouse DNA acylated with 35S-TBM-NHS
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Figure 5.4 Dosing regimen for the newborn mouse lung adenoma assay
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Figure 5.5 HPLC chromatogram of acylated mouse sample from newborn mouse lung
adenoma assay
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Figure 5.6 Persistence of BaP-DNA adduct in male mice
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Table 5.1 Modification levels in BaP treated mouse liver determined on the basis of the 3H-
BaP internal and the "S-acylation products.
Table 5.2. Summary of the percentages of animals with at least one tumor.
Total # of Mice with Lung Tumors
Litter 5
4/4 (100%)
4/6 (67%)
Litter 40
5/5 (100%)
6/6 (100%)
Total # of Mice with Liver Tumors
Litter 5
4/4 (100%)
0/6 (0%)
Litter 40
2/5 (40%)
0/6 (0%)
Male
Female
Male
Female
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Table 5.3. Lung and liver tumor frequency after 5.5 months in male mice
dosed with 210 ýtg BaP in newborn mouse lung adenoma assay.
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Tumorigenicity in Male CD-I Mice
Litter 5 Litter 40
# of Tumors per animal
Animal Lung Liver Lung Liver
1 10 5 1 1
2 29 1 3 3
3 3 0 2 2
4 7 4 4 4
5 - - 5 5
Table 5.4. Lung and liver tumor frequency after 5.5 months in female mice
dosed with 210 gg BaP in newborn mouse lung adenoma assay.
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Tumorigenicity in Female CD-I Mice
Litter 5 Litter 40
# of Tumors per animal
Animal Lung Liver Lung Liver
1 5 0 1 0
2 3 0 3 0
3 5 0 1 0
4 0 0 2 0
5 1 0 2 0
6 0 0 1 0
Chapter 6. DNA Adducts of Benzo(a)pyrene: Human Studies
6.1 Introduction
There is extensive evidence from 32P-postlabelling studies and immunological data
demonstrating that BaP-DNA adducts are present in humans. Even in these cases, it was difficult
to distinguish one related adduct from another. Additionally, care must be taken when interpreting
fluorescence data because the formation of tetraols can disproportionately contribute to the overall
fluorescence yield (Geacintov et al., 1987). Dipple (1994) stated "It is perhaps unreasonable to
expect that specific hydrocarbon-nucleoside adducts can be detected in man, but with improved
methods this aim may be realized sooner than expected". This chapter describes another step to
address this issue through the application of the ADAM method to detect BaP-DNA adducts in
human tissue DNA samples.
The ADAM procedure has been shown to successfully analyze BaP-modified calf-thymus
DNA. These optimal conditions were also used to analyze in vivo tissues from BaP-treated mice.
Because of the promising results seen in the mouse samples, the next step was to investigate human
tissues. This chapter describes use of the ADAM method to analyze 2 sets of human samples for
BaP-dGuo adducts. One set of human samples involved tissue that was collected during surgery to
remove lung tumors. The other set of samples was breast tissues removed from cancer patients,
fixed then embedded in paraffin. The previous chapter described the success of to DNA isolation
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from embedded tissues and the ability to detect BaP-dGuo adducts with the ADAM method. This
knowledge could then be applied to embedded human samples. Since pathology laboratories treat
tissue biopsies of cancerous and noncancerous tissues with fixative and embed them in paraffin, a
large number of embedded human tissues are stored in pathological archives. These samples are
valuable because they often have a medical history attached to each tissue.
This chapter describes the detection of BaP-dGuo in human tissues with the ADAM
method. Figure 6.1 describes the strategy for the detection of BaP-DNA adducts in human
samples. If the tissues are fixed-embedded, the paraffin was removed and treated the same as the
frozen tissues. The tissues were homogenized, the DNA was isolated and enzymatically hyrolyzed.
The modified nucleosides were purified with immunoaffinity chromatography, spiked with an
internal standard and acylated with 35S-TBM. The acylation products were quantified and the
results are reported here.
6.2 Materials and Methods
SL-9 (MolTox); calf thymus DNA, glucose-6-phosphate, glucose 6-phosphate
dehydrogenase, Nuclease P1, alkaline phosphatase from bovine intestinal mucosa (50% glycerol)
(Sigma Chemical Co.); Benzo(a)pyrene (Aldrich); 3H-BaP (Amersham); anti-benzo(a)pyrene-r-7,t-
8-dihydrodiol-t-9, 10-epoxide (±) (NCI Chemical Carcinogen Reference Standard Repository); 35S
-Methionine (5mCi, 1000mCi/mmol) (NEN/Dupont); snake venom phosphodiesterase (ICN); Sep-
pak C18 environmental cartridge (Waters); methanol (Baxter); xylene, chloroform, benzene,
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dichloromethane, ether, ethanol, tetrahydrafuran, pyridine di-tert-butyldicarbonate, triethylamine,
dimethylfomamide, (Mallinckrodt).
6.2.1. Acylation reagent preparations
All reagents were purified and rigorously dried prior to use in the acylation. DIC was
distilled under reduced pressure, and TEA was distilled over sodium metal. Both reagents were
chromatographed on Sephadex LH-20. THF and pyridine were distilled over sodium metal and
benzophenone (as an indicator) and calcium hydride for 2 and 10 days, respectively. All purified
reagents were aliquoted into dry ampules (prewashed with methanol, dried at 5000 C for 4 hours
and aspirated with argon), sealed under vacuo and stored at room temperature. Aliquots of
approximately 0.1 g TBM were weighed, dried in vacuo for 5 hours and stored in a dessicator at
40C until used. Prior to use in the acylation reaction, the TBM was dissolved in pyridine at a
concentration of 2M.
6.2.2 Removal of Paraffin (from archival tissues)
Paraffin embedded human breast tissues (provided by Dr. F. Perera) were stored at
ambient temperatures until the paraffin was removed with xylene (1.2ml, 470C for 135 minutes).
The samples were centrifuged 14,000 rpm for 2 minutes. The solvent was then removed, 1.2ml of
xylene was replaced and further incubated for 15 minutes. This process was repeated once more
before successively soaking the samples twice for 5 minutes in Iml of 100%, 95%, and 75%
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ethanol and water. Samples were temporarily stored at 40C for 18 hours. Each sample was
washed with 1 ml H20 and stored at -200 C until ready for DNA isolation.
6.2.3 DNA isolation
DNA was isolated from the frozen human lung samples and fixed human breast samples
according to the method of Davis et al (1986). The breast tissues were provided by Dr. P. G.
Shields. Fifty pg of the human lung samples were analyzed. When possible 100 ýg of the human
embedded breast tissues were analyzed. Samples that did not contain 100 pg, all of the DNA was
analyzed. Briefly, the homogenates were incubated with proteinase K at 370 C, extracted with
phenol:chloroform:isoamyl alcohol. The DNA was ethanol precipitated and dissolved in SSC
buffer (5.4 mM trisodiumacetate, 30mM NaC1). The DNA was treated with DNase free-RNase
for 30 minutes at 370C. The DNA was extracted with phenol:choroform, ethanol precipitated,
washed with 70% ethanol, dried and dissolved in 1 ml 10mM Tris buffer (pH 7.4) and stored at
4oC overnight. DNA concentration was determined by UV absorbance. The ratios of
A 2 60 nm/A 2 80 nm ranged from 1.83-1.90.
6.2.4 Enzymatic hydrolysis of DNA
DNA samples were hydrolyzed to mononucleosides using NPI , snake venom
phosphodiesterase and alkaline phosphatase. 200 jig DNA in 0.1 M sodium acetate buffer were
hydrolyzed with NP1 (84.5 units NP1/mg DNA) for one hour at 37oC. Snake venom
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phosphodiesterase (0.9 SVPD units/mg DNA) and alkaline phosphatase (16.7 units AP/mg DNA)
were then added and the incubation was continued at 370 C for one hour.
6.2.5 Immunoaffinity chromatography
Before acylation with 35S-TBM, the eznymatic digests were purified via immunoaffinity
chromatography. Immunoaffinity columns (400 ld) containing PAH specific monoclonal antibody
were prepared with gel stored at 40C for several days prior to the purification. Each column was
equilibrated with H20 before the DNA digests were diluted in 5ml H20 and loaded 3 times. The
columns were washed with 20 ml H20 before being eluted with 100% (8 ml) methanol. The
sample volume was reduced to -100 ~l and spiked with 25 fmol of 3H-BaP-dGuo as an internal
standard. The samples were dried under reduced pressure and stored in a dessicator at -200 C until
acylation.
6.2.6 Acylation with of Human Tissues with 35S-TBM
The dried samples were resuspended in pyridine containing TBM (5 x 104 molar
equivalents) and DIC (ratio of 1:16, TBM:DIC). Self-manufactured 35S-TBM was added and the
mixture was incubated for 2 hours at 370 C. The samples were dried under reduced pressure and
stored at -200C until hexane extracted. The samples were resuspended and hexane extracted as
previously described and analyzed via RP-HPLC. The water:methanol gradient used was isocratic
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40% methanol for 13 minutes, linear gradient of 40-60% methanol for 10 minutes, isocratic at 60%
for 12 minutes, linear gradient of 40-60% for 20 minutes, and isocratic 100% for 25 minutes.
6.2.7 Quantitation of BaP-DNA adducts
The amount of BaP-adduct present in the tissues was based on the radioactivity 35S as
determined by the following evidence: (1) the area under the peak between 58-60 minutes was
considered to be the reaction product because the retention time is the same as that of the
BaP-adduct reaction product; and (2) a linear correlation was found between the amount of
3H-BaP-dGuo reacted and the amount of 35S incorporated into acylation products.
The chromatograms generated by the reagent controls were subtracted from the radio-
chromatograms generated by the samples. Since the samples were spiked with an internal
standard, the area under the peak(s) of interest were calculated using the area of the acylated
internal standard. The amount of of BaP-deoxyguanosine (fmol) was determined and the internal
standard was subtracted from the total amount calculated. This value was translated to number of
adducts per 108 nucleotides based on the amount of DNA used for the study. It was assumed that
a human diploid genome contained 12xl09nt to calculate the number of adducts per cell. Simply,
the number of adducts/l08nt were multiplied by 120 to calculate the number of adducts per cell.
6.3 Results and Discussion
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A total of 15 lung samples were analyzed. The results are summarized in Table 6.1. The
range of the adduct levels found was 2-426 adducts/108 nt (0.05-147 fmole/ltg DNA) with an
average of 13,185 adducts per cell. Adducts were not detected in 1 sample. Figure 6.2 shows a
representative chromatogram of an acylated adduct profile from lung DNA. (Samples that gave a
negative number after subtracting the controls were denoted as ND.)
The HPLC profiles produced by the acylation of BaP-dGuo with 35S-TBM have similar
retention times as embedded human breast samples acylated with 35S-TBM. Figure 6.3 shows a
representative radio-chromatogram of a breast tissue DNA acylated with 35S-TBM. A total of 14
embedded breast tissues were deparaffinized and acylated. The range ofadduct levels shown in
Table 6.2, was 35-1764 adducts/10 8 nt (1-54 fmole/tg DNA) with an average of -44,000 adducts
per cell. Adducts were not detected in 2 samples and denoted as ND. As described in chapter 5,
when calculating the modification level, there was a 20-fold difference between frozen tissues and
tissues fixed in formalin for 168 hours. Based on internal standards the calculated amount of BaP
was accurate. As a result, the modification levels (Table 6.3) were divided by 20 to give a more
accurate representation of what the adduct levels/cell might have been if the tissues had not been
fixed and embedded.
The acylation reaction conditions found to be optimal for in vitro modified DNA and 2'-
deoxyguanosine were found to produce comparable results with BaP-dGuo adducts in mouse and
human tissues. In both cases of human sample analyses, the acylation products of human lung and
embedded human breast samples have the same retention time as the peaks produced by the
acylation of BaP-dGuo from modified calf thymus DNA and DNA from mice dosed with 3H-BaP.
It is reported here that DNA from embedded tissues can be isolated and analyzed for BaP-DNA
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adducts by the ADAM procedure. The use of DNA from embedded tissues will allow the analysis
of archival tissues.
In addition to being able to measure BaP-DNA adduct levels in human samples both
frozen and embedded, the method has proven to be at least as sensitive as other DNA-adduct
detection methods eg., 32P-postlabelling, immunological methods and fluorometric methods.
Bartsch et al., (1992) examined carcinogen metabolism and human lung tissues and the effect of
tobacco smoking. Since cigarette smoking is the strongest risk for lung cancer so far identified
(IARC, 1986), 32 P-postlabelling was used to measure the adduct levels in smokers and ex-smokers.
Smokers were found to have significantly higher levels of BaP-DNA adducts (mean of 5.38 +
3.19/108 nt) than ex-smokers (mean of 1.09 adducts/10 8 nt + 0.084). PAH-DNA levels were
determined by ELISA in WBC taken from residents in Poland where the air pollution is high. The
mean PAH-DNA level in exposed residents was 30.4 adducts/10 8nt (Perera et al., 1992). In 1994,
Rojas et al., validated a new fluorometric that can measure 1 BPDE adduct per 108 unmodified
nucelosides. The quantity of WBC DNA required varied between 5 and 500ig and the assay was
applied to WBC DNA samples from lung cancer patients. High levels of BPDE adducts ranging
from 62-533 adducts/108 nucleotides, were found in six out of the seven lung cancer patients. In
WBC DNA samples from healthy individuals the BPDE-DNA adducts were much lower (4-10
adducts/l08nt)
It has been shown that the ADAM method can be used to analyze BaP-DNA adducts in
human samples and that the ADAM method is as sensitive as the above mentioned methods. It
also has several advantages. (1) The method is easier than 32P-postlabelling because the
radioactive shielding is not required and the chemical acylation reaction is not impeded by the
121
limitations of enzymatic reactions; (2) The samples can be examined for more than one family of
compounds. Since the eluate from the immunoaffinity purification was saved, other adducts could
be isolated using a different antibody; (3) The method is not dependent on the availability of
antibodies. The acylation reaction products must first be determined through the use of a standard
for the compound of interest. The unmodified nucleosides can be removed from the enzymatic
hydrolysate with a C18 column. The remaining modified nucleosides are acylated and the reaction
products can be quantified; (4) Fluorescence techniques are sensitive, but require the compound of
interest to have fluorescence characteristics. The ADAM method does not use fluorescence in the
quantitation of the adducts and therefore, can be applied to compound that lack fluorescence. The
use of the ADAM method to detect BaP-DNA adducts will be useful in analyzing random human
lungs for BaP-dGuo adduct.
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Figure 6.1 Scheme for the detection of BaP-DNA adducts from human tissues
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Figure 6.2 HPLC chromatograms of the acylation of 3H-BaP-dGuo with 35S-TBM
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Figure 6.3 Radio-chromatograms of acylation products of DNA modified with BaP
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Table 6.1. BaP modification levels of human lung samples determined by the ADAM method.
Fifty jtg of DNA used for the analysis.
Human Lung
Adduct/108 Femtomole Adducts/Cell
Sample nucleotides BaP/pg DNA T= 13,185
F 426 14.7 51,120
K 58 2 6,960
P 2 0.05 240
R 210 7.56 25,200
N, 12 0.36 1,440
N2  55 1.64 6,600
C, ND ND ND
C2 116 3.48 13,920
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Table 6.2. BaP modification levels of human breast samples determined by the ADAM method.
Embedded Breast
Adduct/108
Sample nucleotides
1 ND
2 484
3 35
4 ND
5 393
7 154
8 243
9 177
10 114
11 296
13 287
14 562
16 673
17 1764
Femtomole
BaPI/pg DNA
ND
15
1
ND
12
5
7
5
4
9
9
17
21
54
AdductslCell
57= 44,000
ND
58,080
4,200
ND
47,160
18,480
29,160
21,240
13,680
35,520
34,440
67,440
80,760
211,680
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Table 6.3. BaP adducts per cell in human breast samples determined by the ADAM method. The
adducts are represented as the raw numbers and then divided by 20. The embedded tissue
modification levels were divided by 20 to account for the 20-fold difference seen between those
seen in frozen and those seen in fixed mouse tissues.
Embedded Breast
Adjusted
Adducts/Cell Adducts/Cell
Sample R= 44,000 5= 2,221
1 ND ND
2 58,000 2,904
3 4,200 210
4 ND ND
5 47,160 2,358
7 18,480 924
8 29,160 1,458
9 21,240 1,062
10 13,680 684
11 35,520 1,776
13 34,440 1,722
14 67,440 3,372
16 80,760 4,038
17 211,680 10,584
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Chapter 7 Conclusions and Recommendations
7.1 Summary of Thesis Results
The ability to measure individual exposure to carcinogens is valuable,
assess cancer risk. The use ofcarcinogen-DNA adducts, specifically BaP-DNA
explored in this thesis to determine their usefulness in evaluating exposure to bei
internal standard was generated to use as a control for the analytical experiments
Several methods were explored to generate a BaP-dGuo standard. Benzo(a)pyr(
was successfully reacted with calf thymus DNA to yield the same profile as whei
is modified microsomally. This standard was used to further develop and adapi
method for the analysis of BaP-DNA adducts. A protocol has been established 1
react benzo(a)pyrene-diol-epoxide with 2-deoxyguanosine.
Two major things were accomplished with the ADAM method. The firs
development and application of the ADAM method. The second was improverr
with 35S-TBM. The successful acylation of 3H-BaP-dGuo with NHS-TBM is re
well. The improvement of the ADAM by the substitution of TBM in the place a
had several advantages. The manufacturing, purity and specific activity can be c,
laboratory. In addition, the efficiency of the reaction is increased to 90%. As a
profile of the reaction products is much cleaner.
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In vivo mouse samples were analyzed for BaP-DNA adducts with the ADAM method.
The HPLC profiles produced by the acylation of BaP-dGuo with 35S-TBM have similar retention
times as embedded human breast samples acylated with 35S-TBM. These have the same retention
time as the peaks produced by the acylation of BaP-dGuo produced with calf thymus DNA, liver
DNA from mice dosed with 3H-BaP (data not shown) and human lung data. The acylation
reaction conditions found to be optimal for in vitro modified DNA and 2'-deoxyguanosine have
been found to produce comparable results with BaP-dGuo adducts in tissues. It is reported here
that DNA from embedded tissues can be isolated and analyzed for BaP-DNA adducts by the
ADAM procedure.
This work also included investigation of BaP-DNA adducts in mice and use of the ADAM
method with human samples. The acylation products of BaP-dGuo, regardless of the source, elute
at the same retention time. The use of 210 [g BaP in the newborn mouse lung adenoma assay
successfully produced tumors. Samples were collected for analysis of BaP-DNA adducts in target
and nontarget organs. It is possible and successfully shown here that DNA can be isolated from
paraffin embedded tissues and analyzed for BaP-dGuo adducts.
7.2 Conclusions
Several conclusions arise from the work. First, 35S content of acylated products was
linearly correlated with the nucleoside adduct concentration over the range from 20 to 1000
femtomoles. Second, adduct levels determined on the basis of 35S acylation were highly correlated
with those determined from the 3H-BaP internal standard in 3H-BaP treated mice. Third, HPLC
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profiles 35S acylation products ofadducts in DNA isolated from mouse tissues and human lung
tissues were identical to authentic standards.
The major conclusions of this thesis research can be summarized as follows:
(1) A BaP-dGuo standard was generated for HPLC analysis.
The HPLC profile was the same regardless of whether the adduct
was generated with BPDE or with microsomes.
A co-injection monitoring the UV absorbance (A3 47 nm) and the radio-labeled
carcinogen 3H-BaP provided two independent measures of the adduct and
demonstrated a reproducible profile.
The electrospray-MS analysis confirmed that the compound had the correct
molecular weight m/z 570.
(2) The ADAM method was further developed and applied to measure BaP-dGuo
adducts.
* The acylation of 3H-BaP-dGuo with 35S-TBM-NHS was successful over a range
of specific activities from 10 Ci/mmol to 1000 Ci/mmol.
* Detection of BaP in a range of 20-1000 femtomoles of BaP-dGuo was
accomplished.
(3) The ADAM method was improved by the substitution of 35S-TBM which can be
synthesized and purified in our laboratory.
A linear relationship was observed between the amount of adduct
versus the amount of 35S acylated products when 3H-BaP was
reacted with 35S-TBM.
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* The improved method has several advantages. The manufacturing,
purity and specific activity can be controlled and reaction efficiency
increased to 90%.
(4) The levels of BaP-DNA adducts were investigated in treated mice.
The 24 hour exposure to 3H-BaP revealed the applicability of the
ADAM method to in vivo samples and the correlation of the
adduct levels based on 3H and 35S validated the method.
Reaction products not present in the reagent control proved
promising in the possibility of analyzing BaP-DNA adducts in
tissues.
It was demonstrated that DNA can be isolated from paraffin embedded tissues
and analyzed for BaP-dGuo adducts.
The use of 210 pg BaP in the newborn mouse lung adenoma assay
successfully produced tumors. Samples were collected for analysis
of BaP-DNA adducts in target and nontarget organs.
The persistence of adduct levels in mice dosed in the newborn mouse assay was
determined based on the 3H-BaP treated mice.
(5) The ADAM method was used to quantify BaP-DNA adducts in human samples.
The adduct levels examined are from DNA isolated from human
lung and embedded breast tissues.
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* The HPLC profiles of the acylation products had the same
retention time as the peaks produced by the acylation of BaP-dGuo
produced from calf thymus DNA and treated mice.
7.2 Recommendations for future work
Further optimization of the ADAM procedure for analysis of BaP-dGuo adducts
This research has produced an optimal method for measuring benzo(a)pyrene-dGuo
adducts. However, there is always the potential for simplifying the method to increase productivity
and ease of use. An improvement in the yield of the adduct during the hydrolysis and purification
steps would be useful. Other areas to explore include adjusting the HPLC chromatography for the
analysis of the acylation products by adjusting the HPLC profile by changing the column
temperature or solvent gradient. For example, a shorter gradient would make it more efficient to
analyze more samples.
Obtain additional informationufrom the tissues collected in the newborn mouse assay
In terms of the newborn mouse lung adenoma assay, there are a few areas that may be of
interest. An examination of DNA isolated from female mouse samples from the newborn mouse
assay would determine if there is a relationship between the DNA-adduct levels and tumor
frequency in the liver. Since there were no liver tumors produced in the female mice, it would be
interesting to determine if adduct levels in female were the same or different than the adduct levels
in the male mice.
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Analyze human samples for additional adducts
A study of the adduct levels in the heart would be a line of experimentation because it has
been reported that other laboratories conducting similar experiments with PAHs found high adduct
levels in the heart but no tumors in the heart. Is this because the turnover cell is much slower than
a liver or lung cell or is better repair by the heart cell the key? These and other questions could be
explored.
It would also be possible to examine histone-BaP adducts in newborn mouse lung adenoma
assay. The histone adducts are the result of the carcinogen covalently binding to the proteins which
the DNA is coiled around. This can be measured with a laser enhanced procedure specific for
benzo(a)pyrene adducts (Ozbal, unpublished data). This would allow comparison of the two
adducts and the carcinogenic correlation of each. The type of relationship which exists will
provide valuable insight into the significance of the adduct levels and the formation of tumors.
The use of DNA from embedded tissues will allow the processing of stores of archival
tissues. The advantages are that medical information can be obtained from the patient to get more
information about the samples and that once the tissues are fixed and embedded, they can last
indefinitely. The phenomenon of the amplified/selection ofBaP-modified DNA from fixed-
embedded tissues needs to be better characterized.
After anti-body purification, Ab column eluates were preserved. These washes can be
repurified using antibodies for other compound. This would allow the examination of the same
human lung and breast tissues for several different families of adducts. These might include
heterocyclic ammines (PhIP, MeIQx), akylating agents, and possibly aflatoxins.
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Broader goals include measuring more human samples in cancer and noncancer patients to
see if there is any relationship on the levels of DNA adducts and tumor formation. It would be
valuable to examine the same tissue to try to detect more than one type of adduct.
The need for more accurate measures of exposure is critical. Each individual has a unique
set of levels of exposure to environmental carcinogens as well as a unique set of susceptibilities to
these carcinogens. The variety may be due to age, sex, or even genetic background. Currently,
one is not able to determine an individual's level of carcinogenic exposure and assess the relative
risk of cancer for that individual with certainty. The generation of tissue specific DNA adducts,
will provide a data base in correlating molecular biomarkers, specifically DNA adducts and cancer.
Although it is clear the carcinogenesis is a multi-step process involving mutations, ineffective
repair, etc. and eventually uncontrollable growth, an established relationship of biomarkers to
exposure will pave the way to accurately answer questions of individual human exposure and may
provide a basis for qualitative risk assessment.
This thesis focused on the use of the ADAM method to measure BaP-dGuo adducts. The
ADAM method can be applied to other nucloside adducts as well. This method, with its
improvements over previous approaches, will allow even more study of the role of PAHs in cancer
formation in humans.
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